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1. Introduction 
Hyponatremia (American English) or hyponatraemia (British English) is defined as 
serum sodium concentration (Na+) <135 mmol/l (Reynolds et al. 2006; Spasovski et 
al. 2014). It is the most common electrolyte disorder and correlated with increased 
morbidity and mortality. 
Hyponatremia poses substantial diagnostic and management problems for 
physicians. The diagnostic challenge comes from several factors, firstly; the 
heterogeneity of hyponatremia as this disorder has multifactorial etiologies and 
several causes may be found in the same patient (Sterns et al. 1994), secondly; 
hyponatremia is not a disease per se but mainly a result from disturbances in water 
hemostasis in most instances (Sterns, 2015). Low serum sodium level is commonly 
a feature or complication of other medical illness although it can be seen as an 
isolated disorder (Simon et al. 2015).  
There is always a need to improve the ways of evaluation of volume status in order 
to improve the diagnosis of hyponatremia. Clinical assessment in American and 
European guidelines takes inferior level in algorithm because it‘s a matter of 
experience and subjective procedure. Particularly, hypovolemic and euvolemic 
hyponatremia are unfortunately difficult to differentiate based on clinical assessment 
(Hoorn & Zietse, 2017). Although the last years have seen improvement in the 
diagnosis of hyponatremia, the evidence base is limited.  
Acute severe hyponatremia can lead to severe neurological consequences due to 
cerebral edema, and that can be lethal if not discovered and adequately treated. 
Even chronic and mild hyponatremia may negatively affect health status, with its 
effect, particularly, on the central nervous system and the bone, causing attention 
deficits, gait instability, falls, osteoporosis, and fractures (Renneboog et al. 2006; 
Gankam et al. 2008; Kinsella et al. 2010; Verbalis et al. 2010), it can significantly 
prolong the hospital stay and increase medical costs (Callahan et al. 2009). Although 
many studies mentioned that patients with hyponatremia were hospitalized for 
significantly longer durations compared to normonatremic patients, however, little is 
known about the factors affecting hospital stay of patients with hyponatremia  
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especially in patients admitted to endocrinology wards. According to Corona et al., 
hyponatremia was associated with up to around $3000 higher hospital costs per 
patient than normonatremic subjects when 8 North American studies were 
considered (Corona et al. 2016). 
  
 
 Review of the literature 
 
 
3 
 
2. Review of the literature 
2.1. Prevalence and incidence 
The frequency of hyponatremia varies notably in clinical studies. This can be 
explained by differences in study population and inclusion criteria of serum sodium 
concentration. The prevalence of hyponatremia is higher in inhospital patients than 
outpatients (Simon et al. 2015) with a hospital incidence of up to 15-30 % (Callahan 
et al. 2009; DeVita et al. 1990; Hawkins, 2003). The incidence is 1-4 % when only 
patients with serum sodium below 131-130 mmol/l are involved (Hawkins, 2003). 
The frequency is higher on ICU admissions; it was 34.3 % according to one study 
(Padhi et al. 2014). 
2.2. Pathophysiology 
Sodium is the major cation of the extracellular space and plays a leading role in 
maintaining blood volume and blood pressure by attracting and holding water, it is 
essential in cellular osmotic pressure and in transmitting nerve impulses. As the 
serum sodium concentration is determined by the amount of extracellular water 
relative to the amount of sodium, it can be regulated by changing intake or output of 
water. Osmoreceptive neurons located in the anterior hypothalamus detect changes 
in cell stretch due to changes in systemic effective osmolality. A decrease in cell 
stretch stimulates these neurons, which leads to both increased release of 
vasopressin from the pituitary gland and increased thirst. Vasopressin increases the 
reabsorption of water from the primitive urine in the distal tubules of the nephron, 
which leads to production of concentrated urine. To prevent persistent thirst, the 
threshold for releasing vasopressin is lower than that for triggering thirst (Verbalis,  
2003). Under normal circumstances, the kidney has the capacity to excrete as much 
as 15-20 L of free water per day (Singhi & Jayashre, 2009). 
When sodium levels in the blood become seriously low, excess water enters the 
brain cells and they swell. To avoid this, a volume-regulatory adaptation starts. 
Excessive extracellular fluid moves into the cerebrospinal fluid within 1-3 hours, 
which is then shunted into the systemic circulation (Gullans & Verbalis, 1993). 
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Additionally, stretching of the brain cells stimulates the following two osmoregulatory 
responses: 
 inhibition of both antidiuretic hormone (ADH) secretion from neurons in the 
hypothalamus and hypothalamic thirst centre. This leads to excess water 
elimination as dilute urine.  
 immediate cellular adjustment with loss of electrolytes, and over the next few 
days, there is a more gradual loss of organic intracellular osmolytes (Gross et al. 
2001). 
In acute hyponatremia, when serum sodium decreases greater than 0.5 mmol/l/h in 
patients with severe hyponatremia (<120 mmol/l), permanent neurologic damage or 
death is the likely outcome. This hyponatremic encephalopathy can be complicated 
by a sequence of events such as the progression of cerebral edema and increased 
intracranial pressure to brain herniation, respiratory arrest, hypoxia, fatal brain 
damage, and death (Soupart & Decaux, 1996). In chronic hyponatremia which is 
notably common in the elderly and among postmenopausal women, encephalopathy 
can develop despite the belief that this condition carries a low risk of morbidity (Ayus 
& Arieff, 1996). Chronic hyponatremia is generally better tolerated than rapid-onset 
hyponatremia due to the ability of the brain to adapt to hypoosmolality. 
Therefore, the chronicity of the condition should be considered during the correction 
of hyponatremia. Acute hyponatremia can be safely corrected more quickly than 
chronic hyponatremia. Too rapid correction of serum sodium can precipitate severe 
neurologic complications (Simon et al. 2015). 
2.3. Classification and etiology  
Hyponatremia can be defined or classified based on serum sodium concentration, 
rate of development, symptoms severity, serum osmolality, and volume status (see 
methodology). 
Although the differential diagnosis is quite broad, hyponatremia can be divided into 
the following clinically useful groupings: 
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Hypertonic hyponatremia 
Patients with hypertonic hyponatremia have normal total body sodium, the presence 
of osmotically active molecules in the serum causes a water shift from the 
intracellular compartment to the extracellular compartment leading to a dilutional 
drop in the measured serum sodium (Simon et al. 2015). Osmotically active 
molecules that create this translocational hyponatremia are like glucose in 
hyperglycemia, mannitol, maltose (used with intravenous immunoglobulin), and 
glycine (by absorption of irrigation fluids during urological or gynaecological surgery) 
(Hillier et al. 1999). 
On the contrary, high urea concentrations in kidney disease may also increase 
measured osmolality but not effective osmolality as urea is not an effective osmole 
because it freely passes across the cellular membrane (Carlotti et al. 2001).  
In osmotic diuresis, non-reabsorbable solutes obligate the renal excretion of Na+ and 
this results in decreased extracellular volume. The continuing intake of hypotonic 
fluids leads to hypovolemia and hyponatremia and the urinary sodium is frequently 
greater than 20 mmol/l (Kumar & Berl, 1998). 
Normotonic hyponatremia 
The plasma water fraction, which is normally 92-94 % of plasma volume decreases 
with a severe increase in fats and proteins. The measured sodium concentration in 
the total plasma volume is respectively reduced, although the plasma water sodium 
concentration and plasma osmolality are constant. This artificial low sodium (so-
called pseudohyponatremia) is resolved now by exchange of the old method of flame 
photometry by direct ion-selective electrode measurement (Simon et al. 2015). 
Hypotonic hyponatremia 
Hypotonic hyponatremia always reflects the inability of the kidneys to handle the 
excretion of free water to match intake with excess water relative to solute in the 
extracellular fluid (ECF). This imbalance can be due to solute depletion, solute 
dilution, or a combination of both (Simon et al. 2015). Generally, hyponatremia is of 
clinical significance only when it reflects a drop in the serum osmolality (i.e. 
hypotonic hyponatremia). 
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It can be divided into the following categories, according to volume status: 
hypovolemic, hypervolemic, and euvolemic.  
Hypovolemic hyponatremia 
Deficiencies in both total body water (TBW) and total body sodium exist, although 
proportionally more sodium than water has been lost. Secondary to intravascular 
depletion there is decreased stretch on baroreceptors in the great veins, aortic arch, 
and carotid bodies with stimulation of sympathetic tone and release of vasopressin to 
maintain blood pressure. This along with decreased renal perfusion, results in 
increased generation of renin and angiotensin which results in an increase in 
aldosterone and reabsorption of sodium in the distal tubules of the kidney and 
subsequent decreased delivery of solutes to distal diluting segments, causing an 
impairment of renal free water excretion. Besides, angiotensin is also a stimulant of 
thirst. Together, these changes lead to hyponatremia (James, 2011). 
Diuretics: diuretic use is one of the most common causes of hypovolemic 
hyponatremia associated with high urinary sodium excretion. Hyponatremia occurs 
frequently with thiazide diuretics. Loop diuretics, by inhibiting sodium chloride (NaCl) 
reabsorption in the thick ascending limb of the loop of Henle, interfere with the 
generation of a hypertonic medullary interstitium and urinary concentration as well as 
dilution. Thiazide diuretics act exclusively in the distal tubule, interfering only with 
urinary dilution.  
Gastrointestinal and third-space losses: secondary aldosteronism develops in 
response to volume depletion and the kidney is forced to respond by conserving 
NaCl. Urinary sodium is usually less than 10 mmol/l and the urine is hyperosmolar. 
In some patients with vomiting and metabolic alkalosis, bicarbonaturia obligates 
execration of sodium as well. In spite of severe volume depletion, the urinary sodium 
may be greater than 20 mmol/l,  the urinary chloride, however, is less than 10 mmol/l 
(Kumar & Berl, 1998). 
Primary adrenal insufficiency: in primary adrenal insufficiency, mineralocorticoid 
deficiency causes renal sodium excretion (Spasovski et al. 2014). The decreased 
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ECF volume together with a deficit in glucocorticoids stimulates non-osmotic release 
of ADH, so hypovolemic hyponatremia with urinary sodium higher than 20 mmol/l, 
especially if associated with a raised serum potassium, urea, and creatinine, 
suggests mineralocorticoid deficiency (Kumar & Berl, 1998). 
Salt-wasting nephropathy: may rarely develop in a range of renal disorders (e.g. 
interstitial nephropathy, medullary cystic disease, polycystic kidney disease, partial 
urinary obstruction) with low salt intake (James, 2011). This can inhibit the kidney's 
ability to re-absorb appropriate amounts of sodium causing hypovolemic 
hyponatremia (Hamdi et al. 2010). 
Cerebral salt wasting (CSW): is seen especially after neurologic surgery, it can also 
seen with other intracranial disorders. Exaggerated renal pressure–natriuresis 
response caused by increased sympathetic tone and dopamine execration might 
cause low renin and renal salt wasting, resulting in reduced plasma volume. Plasma 
renin and aldosterone levels fail to rise appropriately in patients with CSW despite a 
reduced plasma volume because of a disruption of the sympathetic tone. Impaired 
free water excretion due to stress-mediated increase in vasopressin also plays a 
role. In addition, the release of one or more natriuretic factors could also play a role 
in renal salt wasting (Kojima et al. 2005; Palmer, 2003). 
Hypervolemic hyponatremia 
Hypervolemic hyponatremia is characterized by significant increase in total body 
water and sodium. The following factors contribute to hyponatremia: 
 misbalanced proportion of venous and arterial volume with neurohumoral 
activation of baroreceptor-mediated vasopressin release, natriuretic peptide 
release leading to water retention and renal sodium loss. 
 secondary aldosteronism with angiotensin II-mediated thirst and pharmaceutical 
blockade of aldosterone-mediated renal reuptake of sodium in many such 
conditions. 
 decreased glomerular filtration rate (GFR) and direct impairment of renal water 
excretion. 
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Urinary sodium excretion is usually <10 mmol/l, and urinary osmolality is high relative 
to serum osmolality (James, 2011). Examples of this type of hyponatremia are liver 
cirrhosis, congestive heart failure, nephrotic syndrome, and severe hypoproteinemia 
(albumin level <1.5-2.0 g/dl) (Simon et al. 2015). 
In congestive heart failure the fall in cardiac output leads to reduce the effective 
arterial blood volume, in liver failure, systemic vasodilation and arteriovenous 
shunting of blood may reduce the effective arterial blood volume and induce the 
same mechanism as described above for hypervolemic hyponatremia. In nephrotic 
syndrome, reduction in oncotic pressure and an increase in filtration across the 
capillary results in tissues edema which in turn decreases circulating blood volume. 
This combination of increased vasopressin release and diuretic can lead to 
hyponatremia (Wang, 2000). In kidney disease the ability to dilute urine and excrete 
free water decreases. The sensitivity to vasopressin decreases, and free water 
removal is no longer tightly regulated but is more and more determined by the 
number of osmolites excreted into the urine (i.e. solute intake). Therefore, 
hyponatremia can easily develop if patients do not adhere to fluid restriction 
(Gradden et al. 2001). 
Normovolemic (euvolemic) hyponatremia 
In euvolemic (dilutional) hyponatremia, total body sodium and thus ECF volume are 
normal or near-normal; however, TBW is increased. 
The syndrome of inappropriate antidiuretic hormone secretion or SIADH (other 
names: Schwartz-Bartter syndrome, SIAD): is characterized by excessive secretion 
of arginine vasopressin (AVP) from the posterior pituitary gland or another origin 
(Babar, 2013). Patients with SIADH fail to suppress AVP release even when plasma 
osmolality falls below the normal osmotic threshold triggering AVP release (Smith et 
al. 2004). Hyponatremia in SIADH is thought to be limited by the 'escape 
phenomenon' in which free urinary water excretion increases and urinary osmolality 
decreases after a few days to re-establish fluid balance. This effect protects against 
excessive water retention and severe hyponatremia and may be caused by reduced 
expression of aquaporin-2 in the collecting ducts (Reynolds et al. 2005). 
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Urinary sodium concentrations are also typically greater than 20 mmol/l on a normal 
salt diet as sodium excretion will match dietary sodium intake (Simon et al. 2015). 
Secondary adrenal insufficiency: under normal circumstances, cortisol exerts a 
negative feedback effect on release of both corticotropin-releasing hormone and 
vasopressin in the hypothalamus. In adrenal insufficiency, persistently low levels of 
cortisol fail to suppress vasopressin and lead to hyponatremia. The production of 
aldosterone is affected in lesser degree in secondary than in primary adrenal 
insufficiency and renal sodium loss does not contribute too much to the development 
of hyponatremia (Faustini & Anagni, 2006). 
Hypothyroidism: although included in many diagnostic algorithms, hypothyroidism 
very rarely causes hyponatremia (Kilpatrick, 2006). Only severe cases of 
hypothyroidism can produce hyponatremia. This may result from a reduction in 
cardiac output and glomerular filtration rate (Abuzaid & Birch, 2015). 
High water and low solute intake: the excess water intake is primarily responsible for 
hyponatremia. Vasopressin activity is absent, which is reflected by an appropriately 
low urine osmolality, usually <100 mOsm/kg. Primary polydipsia may occur in 
combination with psychiatric disorders such as schizophrenia. This problem may 
even be aggravated by centrally acting drugs used to treat psychiatric disease. 
The amount of water that the kidneys can remove on a daily basis depends on solute 
excretion and hence solute intake. If solute intake is low relative to water intake, the 
number of available osmolytes can be insufficient to remove the amount of water 
ingested. This is seen in patients with anorexia nervosa, beer potomania and so-
called ‗tea and toast‘ hyponatremia (Thaler, 1998). Same mechanism is postulated to 
cause acute hyponatremia is associated with ultra-endurance athletes and marathon 
runners. 
Other causes of hyponatremia may include: 
Nonsteroidal anti-inflammatory drugs (NSAIDs): NSAIDs use may increase the risk 
of development of hyponatremia by hindering prostaglandin formation and 
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consequently a decrease in renin generation and free water excretion. Prostaglandin 
decreases NaCl reabsorption in the thick ascending limb of Henle (eventually 
reducing medullary tonicity) and ADH action in the collecting duct (Baker et al. 2005). 
Figure 1 - Cartoon on the development of hyponatremia with NSAIDs use 
 
Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit generation of prostaglandin E2 which 
mediates renin release, reducing medullary tonicity and ADH action in the collecting duct 
 
 
Nephrogenic syndrome of inappropriate antidiuresis (or NSIAD): is a SIADH-like 
clinical and laboratory picture but with undetectable plasma AVP levels. It is a rare 
condition, infrequently seen in males and discovered in infants who present with 
neurologic symptoms secondary to hyponatremia. This hereditary disorder is 
secondary to mutations in the V2 vasopressin receptor and results in constitutive 
activation of the receptor with high cAMP production in the collecting duct cells 
(Feldman et al. 2005). 
2.4. History and clinical presentation 
Patients may present to medical attention with symptoms related to low serum 
sodium concentrations. However, in many patients hyponatremia is recognized 
secondarily and they present due to manifestations of primary disease, incl. heart 
failure or renal failure (Bettari et al. 2012). Symptoms of hyponatremia could be 
subtle or unrecognised such as reduced attention level, increased falls and trauma, 
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altered posture and gait in mild hyponatremia (serum sodium level >130 mmol/l) 
(Schrier, 2010; Decaux, 2006). In moderately severe cases, the patients may 
become confused, have nausea and headache. Severe hyponatremia (serum 
sodium levels usually <115 mmol/l), can presented with fatal complications and overt 
neurologic symptoms resulting from intracerebral osmotic fluid shifts and brain 
edema (hyponatremic encephalopathy) together with seizures, cardiorespiratory 
distress, deep somnolence or even coma (Glasgow Coma Scale GCS ≤8) 
(Spasovski et al. 2014; Simon et al. 2015). Osteoporosis and sustain bone fractures 
are more frequent in hyponatremic patients (Renneboog, 2006; Hoorn et al. 2011; 
Verbalis et al. 2010). 
Obtaining a detailed medication history is important because many medications may 
precipitate hyponatremia. A dietary history with reference to salt, protein, and water 
intake is useful as well (Simon et al. 2015). Examination should include orthostatic 
vital signs and an accurate assessment of volume status. 
2.5. Investigations 
There are three key parameters help in establishing the primary underlying etiology 
of hyponatremia beside history and physical examination: 
 
- serum osmolality: it readily differentiates between true hyponatremia 
(hyponatremia with a measured osmolality <275 mOsm/kg always reflects 
hypotonic hyponatremia) and pseudohyponatremia, or hypertonic hyponatremia 
(Spasovski et al. 2014; Simon et al. 2015) 
- urine osmolality: helps to distinguish etiologies associated with impaired free 
water excretion from polydipsia, in which free water excretion consider being 
normal. In hyponatremia urine osmolality greater than 100 mOsm/kg indicates 
impaired ability of the kidneys to dilute the urine. This is commonly secondary to 
ADH elevation (Simon et al. 2015). 
- urinary sodium concentration: it is important to collect the serum and urine 
sample around the same time for appropriate interpretation of the values. 
European guideline group selected a concentration threshold of 30 mmol/l 
because several studies indicated good sensitivity and acceptable specificity in 
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distinguishing hypovolemia from euvolemia or hypervolemia (Musch et al. 2001; 
Fenske et al. 2008). A urinary sodium concentration ≤30 mmol/l suggests low 
effective arterial blood volume, even in patients on diuretics (Schrier, 1988). 
 Other laboratory tests that will help in the diagnosis: 
Uric acid: in SIADH, serum uric acid levels are generally reduced; this is due to 
reduced tubular uric acid reabsorption. 
Serum potassium: if both hypokalemia and metabolic alkalosis are present, consider 
diuretic therapy or vomiting as the cause of hyponatremia. If hyperkalemia and 
metabolic acidosis coexist with hyponatremia, consider hyperglycemia, adrenal 
insufficiency and volume depletion leading to acute kidney injury (Simon et al. 2015). 
Serum cortisol, thyroid-stimulating hormone (TSH), free thyroxin (FT4) 
measurement: hyponatremia associated with cortisol deficiency, such as primary or 
secondary hypoadrenalism, commonly presents subtly and may go undiagnosed. A 
random cortisol level check, especially in acute illness, can be misleading if the level 
is normal (when it should be high). Testing for adrenal insufficiency and 
hypothyroidism should be part of the hyponatremic workup, as the disorders respond 
promptly to hormone replacement (Simon et al. 2015). 
Glucose: see methodology 
Measurement of vasopressin: based on its little usefulness in the work up of 
hyponatremia its measurement is not indicated. However, copeptin may be useful if 
there is more solid data available from clinical studies (Spasovski et al. 2014). 
2.6. Treatment 
In hyponatremia, there is a risk of brain edema before adaptation (<48 h) because 
the lower extracellular osmolality enhances a shift of water into the cells (Giuliani & 
Peri, 2014). However, once adaptation is completed, brain cells can again maintain 
damage with rash elevation of the serum sodium concentration. Breakdown of the 
myelin can yield what is called the osmotic demyelination syndrome (Hoorn & Zietse, 
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2017). Acute hyponatremia can be safely corrected more quickly than chronic 
hyponatremia (Simon et al. 2015). If classifying hyponatremia as acute or chronic is 
not possible, hyponatremia is considered as being chronic; unless there are reasons 
to suspect it is acute (see methodology). 
Hypotonic hyponatremia represents the situation where hyponatremia need to be 
treated; the followings are general lines in treatment such cases: 
- administration of isotonic saline to patients who presented with hypovolemia to 
replace the reduced intravascular volume.  
- fluid and salt restriction to treat patients who are hypervolemic, plus loop 
diuretics, and correction of the underlying condition. The use of a V2 receptor 
antagonist may be considered. 
- for euvolemic, asymptomatic hyponatremic patients, free water restriction (<1 
l/day) is generally the treatment of choice. Correction of underlying condition, and 
in SIADH patient, who persistently hyponatremic despite water restriction and 
correction of possible cause, V2 receptor antagonist are indicated. 
In the treatment regimen of patients with severe symptomatic hyponatremia (e.g. 
seizures, severe neurologic deficits), hypertonic (3 %) saline may be included 
(Simon et al. 2015). 
2.7. Prognosis 
Even when comorbid conditions are taken in consideration, people with a mildly 
decreased serum sodium concentration have a 30 % higher risk of death and 14 % 
longer hospitalization to those without hyponatremia (Upadhyay et al. 2009; Wald et 
al. 2010). However, the relationship between the severity of hyponatremia and 
mortality remains a matter of discussion and the underlying disease causing 
hyponatremia may be more responsible for the mortality than hyponatremia per se 
(Krummel et al. 2016). 
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3. Objectives 
General: 
There is no data published on the spectrum of etiologies in Mecklenburg-Western 
Pomerania. In Rostock, it is unclear, what the most likely diagnosis is when a patient 
is diagnosed with hyponatremia. 
Therefore, the aim of our study is to identify the etiologies of hyponatremia and to 
improve the management of hyponatremia by evaluating the diagnostic value of 
clinical, hematological, biochemical, and hormonal parameters. Blood and urine 
sample were taken from patients by admission and discharge, additionally non-
invasive test to measure body composition was performed on admission. 
More specifically, the following goals are to be aimed at: 
- characterization of the distribution of patients with hyponatremia by age, sex, 
BMI, onset, serum sodium concentration, volume status, and seasons 
- identification the factors affecting the length of hospital stay in patients with 
hyponatremia 
- to describe the comorbid conditions and clinical presentation of patients with 
hyponatremia 
- to identify the etiologies of hyponatremia 
- to improve the management of hyponatremia by evaluating the diagnostic value 
of hematological, biochemical, hormonal, and BIS parameters in identifying the 
volume status and etiology of hyponatremia 
- evaluation of the diagnostic value of some clinical, paraclinical parameters, 
including blood pressure, attention level, serum creatinine, urea, uric acid,  serum 
and urinary sodium, potassium and osmolality and hormonal like aldosterone , 
renin, N-terminal prohormone of brain natriuretic peptide (NT-proBNP)  and their 
reflection of effectiveness of therapy by discharge. 
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4. Patients and methods 
4.1. Study design 
The SHIP-PAGE study (steroid hormones in patients with pituitary, adrenal or 
gonadal endocrinopathies) allows the analysis of patients with disorders in salt 
homeostasis or sodium regulation. Its protocol was approved by the Institutional 
Ethics Committee of the Rostock University Medical Center (# A 2016-0088). 
This study is a descriptive prospective study. It was conducted from October 15, 
2014 to October 15, 2015 at the Division of Endocrinology and Metabolism of the 
Rostock University Medical Centre. 
Inclusion criteria: we included all patients, who were admitted with hyponatremia with 
serum sodium ≤130 mmol/l. Inclusion was possible on weekdays as daily clinical 
assessment of volume status and bioelectrical impedance measurements were 
carried out by the investigator. 
Exclusion criteria: we excluded patients who did not complete the main 
investigations to identify the cause, who refused to participate in the study or left the 
hospital before identifying the cause and establishing specific therapy. 
Case finding, history taking and clinical assessment 
Initial case finding was based on sodium measurement ≤130 mmol/l on admission, 
sodium measurement is a routine laboratory investigation performed for all patients 
admitted to medical wards at Rostock University Medical Centre. 
Data collection was performed by an interview-guided questionnaire. The sources of 
information were the patients or attending relatives, they were included after 
obtaining an informed written consent. History, especially daily water intake, salt 
consumption, and current medication were the sources of information as well as 
medical plans and reports written by treating physicians (a list of drugs was included 
in the questionnaire). 
Evaluation of attention level (coin test) was performed in all the patients on 
admission with the exception of known or suspected dementia, in whom mini mental 
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state tests were performed. Clinical evaluation of extracellular status to determine 
volume status was performed for every patient. Each patient underwent a complete 
physical examination to evaluate extracellular volume status with special attention to 
orthostatic changes in blood pressure and pulse rate, jugular venous pressure, skin 
turgor, hydration of mucous membranes, presence of edema or pulmonary 
congestion signs. Evaluation of extracellular fluid volume status and the response to 
therapy, weight and input output charts monitoring was performed for most of days of 
admission. 
Laboratory and bioelectrical impedance measurements 
Blood for a complete hemogram, blood glucose, lipid profile, thyroid function test 
(TSH and free T4), serum albumin, renal function test (creatinine, urea), uric acid, 
CRP, NT-proBNP, morning serum cortisol, renin, aldosterone, serum and urinary 
sodium, potassium, and osmolality were determined on admission. 
Clinical evaluation, urea, creatinine, uric acid, NT-proBNP, morning renin and 
aldosterone, serum and urinary sodium, potassium, and osmolality were repeatedly 
determined on the day of discharge. 
Serum and urinary osmolality were measured using cryoscopy method by Osmomat 
030 -freezing point osmometer- (Gonotec, Berlin). Chemical analysis was performed 
by UniCel DC 800 synchron clinical systems (Beckmann Coulter) while TSH, free 
T4, cortisol, and NT-proBNP have been measured by electrochemiluminescence  
immunoassays, including the ECLIA Cobas e411 (Roche, Mannheim). Aldosterone 
and renin were manually pipetted and have been measured by RIA-tests with the 
gamma counter LB 2111 multi crystal gamma counter (Berthold, Germany). In 
addition, body composition was assessed by bioelectrical impedance on a body 
composition monitor instrument version 3.3.0.1637 (Fresenius, Homburg) for most of 
patients on admission. 
The cause of hyponatremia in every patient was discussed by a panel of three 
investigators, including me and two consultants in Endocrinology. The likely causes 
and the main cause of hyponatremia were identified based on history, clinical 
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assessment and paraclinical investigations, and sometimes the response to therapy. 
Decisions about the management of hyponatremia were not directly influenced by 
our study and left primarily to the responsible team of physicians. 
 
Figure 2 - Clinical work-up of patients with hyponatremia 
 
This figure shows diagnostic algorithm for hyponatremia based on European guidelines (modified 
from Spasovski et al. 2014) 
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4.2. Definitions of the variables and classifications: 
Age groups 
We divided the patients into the following groups: 
- <50 years 
- 50-70 years 
- >70 years. 
 
Classification of hyponatremia according to serum sodium concentration 
We classified the patients into the following categories: 
- hyponatremia with a serum sodium concentration 126-130 mmol/l 
- hyponatremia with a serum sodium concentration 121-125 mmol/l 
- hyponatremia with a serum sodium concentration 120  mmol/l. 
 
Classification of hyponatremia according to the onset 
Hyponatremia was classified as: 
- acute hyponatremia that is documented to exist <48 h. 
- chronic hyponatremia that is documented to exist for at least 48 h. 
Cases of hyponatremia, who could not be classified, were considered as chronic 
unless this opposed by clinical clues or information from the case history and drugs 
or conditions associated with acute hyponatremia (<48  h) (Spasovski et al. 2014): 
- postoperative phase 
- post-resection of the prostate, post-resection of endoscopic uterine surgery 
- polydipsia 
- exercise 
- recent thiazides prescription in combination with medication to interfere with 
generation or action of renin, angiotensin, and/or aldosterone, desmopressin, 
recently started terlipressin, 3,4-methylenedioxymethamfetamine (MDMA), 
cyclophosphamide (i.v.), oxytocin 
- colonoscopy preparation. 
 
Classification of hyponatremia according to serum osmolality 
Hyponatremia was classified according to effective serum osmolality as follows: 
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 hypotonic hyponatremia (plasma osmolality <275 mOsm/kg) 
 isotonic hyponatremia (plasma osmolality 275-300 mOsm/kg) 
 hypertonic hyponatremia (plasma osmolality >300 mOsm/kg). 
 
Clinical classification of hyponatremia according to volume status 
Volume status assessment was based on history, clinical examination, laboratory 
findings, daily assessment and sometimes treatment response. Hyponatremia is 
classified according to a clinically assessed volume status, as follows: 
 
Hypovolemic hyponatremia 
Diagnosis was made from history of extracellular volume depletion due to: 
- non renal sodium loss such as gastrointestinal fluid loss e.g. vomiting, diarrhea or 
decrease water and salt intake. 
- renal sodium loss as usage of diuretics.  
Besides, clinical signs of hypovolemia were used and included: 
- dry skin and mucous membranes, thirst and decreased urine output, darkness in 
urine color (Armstrong scale), a weak and sometimes fast pulse, orthostatic 
hypotension, history of dizziness or lightheadedness and sometimes fainting. 
 
Hypervolemic hyponatremia 
Was diagnosed based on history of heart failure, renal failure, hepatic cirrhosis or 
nephrotic syndrome with some of the following manifestations: 
- exertional dyspnea and/or dyspnea at rest and orthopnea 
- crackles on auscultation 
- jugular vein distension 
- ascites  
- edema particularly feet and ankles  
- manifestation of  pulmonary congestion on chest X-ray 
- absence of historical and clinical evidence of volume depletion (Lewis, 2011). 
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Euvolemic hyponatremia 
Euvolemic hyponatremia was diagnosed in absence of a reliable history or clinical 
signs of hypo- or hypervolemia. 
 
Urinary osmolality 
Reference range with random urine sample is 50 to 1200 mOsm/kg. Urine 
osmolality falling below 100 mOsm/kg of water in this setting, the hyponatremia is 
probably caused by intake of excess water with low solute intake like in polydipsia, 
anorexia nervosa, beer potomania and what‘s called tea and toast eating habit 
(Thaler et al. 1998; Musch et al. 2003). 
 
Urinary sodium 
Hyponatremic cases were classified according to urinary sodium excretion into: 
- increased urine sodium concentration (>30 mmol/l) 
- decreased urine sodium concentration (≤30 mmol/l) (Spasovski et al. 2014, Musch 
et al. 2001). 
 
Serum sodium to urinary sodium to (serum potassium)2 to urinary potassium  
(SUSPPUP) 
Is an expression of sodium retention in comparison to the amount of renal potassium 
loss that happens in exchange for sodium. 
SUSPPUP = serum sodium : urinary sodium / (serum potassium)2 : urinary 
     potassium. 
A sample of spontaneous urine was collected (fasting state). Sodium and potassium 
values were measured in both serum and urine (Willenberg et al. 2009). 
 
The trans-tubular potassium gradient (TTKG) 
Is an index reflecting the conservation of potassium in the cortical collecting ducts 
(CCD) of the kidneys. It is useful in diagnosing the causes of hyperkalemia or 
hypokalemia. The TTKG estimates the ratio of potassium in the lumen of the CCD to 
that in the peritubular capillaries. The following is the formula for calculating the 
TTKG: TTKG = urinary K / plasma K ÷ urine osmolality / plasma osmolality. 
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(this formula is valid only when U osm >300 mOsm/kg and U Na+ >25 mmol/l (Choi 
& Ziyadeh 2008). 
 
Coin test 
We used this test to evaluate the attention level of patients by giving the patient 
coins, some of them were old and not used any more or from other countries and we 
asked the patient to give us 4.84 Euro with shortest possible time with measuring the 
time with timer. 
The following table illustrates the reference values. 
Note: patients with dementia, difficulty in vision or hearing were given 112 sec. 
 
Table 1 - Coin test or evaluation of patient‘s attention level 
age (years) performance time (sec) 
–2 SD Mean +2 SD 
18-39  5.1 22.1 39.3 
40-49 4.3 29.0 53.7 
50-59 5.4 38.5 71.5 
60-80 9.5 51.6 112.8 
SD; Standard deviation 
 
Overhydration (OH) 
Bioelectrical impedance spectroscopy BIS was carried out using the Body 
Composition Monitor BCM with four conventional electrodes being placed in the 
patient, who is lying in the supine position: two in the hand and two in the foot. OH or 
excess fluid represents an expansion of only the extracellular water ECW, whereas 
intracellular water ICW remains unchanged. The difference between "normal" ECW 
and measured ECW is the excess fluid, OH. With the following reference range (–1 - 
+1 L), negative OH means that the patient is under- or dehydrated. 
4.2.1. Etiologies 
Syndrome of inappropriate antidiuretic hormone secretion or SIADH 
Laboratory findings include 
- effective plasma osmolality <275 mOsm/kg  
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- urine osmolality >100 mOsm/kg of water during hypotonicity 
- clinical euvolemia 
- urine sodium concentration >30 mmol/l with normal dietary salt and water intake 
- absence of adrenal, thyroid, pituitary or renal insufficiency 
- no recent use of diuretics agents. 
Other findings: 
- serum uric acid <0.24 mmol/l (<4 mg/dl) 
- serum urea <3.6 mmol/l (<21 mg/dl) 
- failure to correct hyponatremia after 0.9 % saline infusion 
- fractional sodium excretion >0.5 % 
- fractional urea excretion >55 % 
- fractional uric acid excretion >12 % 
- correction of hyponatremia through water restriction (Spasovski et al. 2014; 
Schwartz et al. 2001; Janicic et al. 2003).  
 
Hyperglycemia 
The following formula is usually recommended to calculate the effect of 
hyperglycemia on hyponatremia: 
- every increase in blood glucose levels by 100 mg/dl (5.55 mmol/l) above the 
normal glucose levels 100 mg/dl (5.55 mmol/l) can decrease sodium levels by 2.4 
mmol/l. 
- at glucose levels >400 mg/dl (22.2 mmol/l), every additional increase of glucose 
by 100 mg/dl (5.55 mmol/l) can decrease sodium levels by 4 mmol/l (Hillier et al. 
1999). 
 
Renal failure 
Acute renal failure is defined as any of the following: 
- increase in serum creatinine SCr by ≥0.3 mg/dl (≥26.5 mmol/l) within 48 hours; or 
- increase in SCr to ≥1.5 times baseline, which is known or presumed to have 
occurred within the prior 7 days; or 
- urine volume <0.5 ml/kg/h for 6 hours (KDIGO, 2012). 
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Chronic kidney disease is defined as: either kidney damage or GFR <60 ml /min/1.73 
m2 for ≥3 months. Kidney damage is defined as pathologic abnormalities or markers 
of damage, including abnormalities in blood or urine tests or imaging studies 
(KDIGO, 2013). 
 
Heart failure 
The diagnosis of heart failure consists of the concurrent presence of either 2 major 
criteria or 1 major and 2 minor criteria according to Framingham criteria (Ho et al. 
1993). 
 
 Hypothyroidism 
The combination of serum TSH levels >20 mU/l with fT4 levels below the reference 
range was defined as diagnostic of severe primary hypothyroidism (Tzoulis et al. 
2015). Serum sodium concentration decreased by 0.14 mmol/l for every 10 mU/l rise 
in TSH (Warner et al. 2006). 
 
Glucocorticoid deficiency (secondary adrenal insufficiency) 
We were used a basal serum cortisol of 450 nmol/l as the cut-off point below which 
glucocorticoid deficiency cannot be excluded (Dorin et al. 2003; Cooper et al. 2003; 
Tzouliz et al. 2015) confirmed by Metyrapone test (Oelker et al. 1996). 
 
Diuretics + Renin angiotensin aldosterone system RAAS affecting drugs 
RAAS affecting drugs including angiotensin converting enzyme (ACE) inhibitors, 
angiotensin receptor antagonists (ARA II), drugs suppress renin release such as 
beta blockers and aldosterone receptor antagonists such as spironolactone – also in 
combination with thiazide or sulfonylurea diuretics. 
 
Drugs  
Drugs other than diuretics that implicated in our study in the genesis of 
hyponatremia, especially euvolemic type, including: ACE inhibitors or ARA II (when 
used unaccompanied with diuretics), desmopressin, antidepressant; selective 
serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants, antipsychotics; 
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phenothiazines or haloperidol, antiepileptics drugs; carbamazepines or valoprate, 
and non-steroidal analgesics. 
 
Diuretics 
Diuretic-induced hyponatremia: was defined as hyponatremia in patients receiving 
diuretics especially: amiloride, triamterene, spironolactone (when used 
unaccompanied with ACE inhibitors, ARA II or beta blockers). 
 
Gastrointestinal fluid loss 
Vomiting or diarrhea. 
 
Decreased water intake 
Normal fluid requirements for adults ≥19 years including plain water, milk and other 
drinks 
Men:  2.6 L/day (about 10 cups) 
Women: 2.1 L/day (about 8 cups) 
(Water Nutrient Reference Values for Australia and New Zealand, 2014). 
 
Psychogenic Polydipsia (PPD) 
Was diagnosed based on history of frequency of drinking due to unnatural thirst and  
passing large volumes of diluted urine, the urine is very dilute before water is 
restricted (<100 mOsm/kg H2O). It achieves an osmolality of >750 mOsm/kg H2O 
after restricting water and giving vasopressin, is diagnostic of PPD (Goldman et al. 
1996). 
4.3. Statistical analysis 
The statistical analysis was done with the help of SPSS 22. For non-parametric 
variables results were expressed as the median of individual data points, comparison 
between patient groups was evaluated by Wilcoxon‘s test for paired and by Kruskal 
Wallis for unpaired data sets. For parametric variables results were expressed as the 
mean of individual data points, comparison between patient groups was evaluated 
by paired samples T Test for paired and by Anova for unpaired data sets. To find out 
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the relationships of qualitative variables, Chi square Test was used. The level of 
significance was considered <0.05. The results were presented in statistical tables 
and graphs. 
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5. Results  
5.1. Baseline characteristics 
During the one year study period, 59 patients were identified as having had a serum 
sodium concentration of 130 mmol/l or less. Nine patients were not included in the 
analysis because treatment of hyponatremia had already been started or they did not 
agree to participate. Finally, 50 patients were included in the final statistical analysis. 
The age of patients ranged from 35 to 93 years with a mean of 72.8 ± 15.8 years. 
Most of patients were females (n= 32, 64 %). The mean sodium level was 120.9 ± 
7.6 mmol/l. The baseline characteristics of patients admitted with hyponatremia are 
illustrated in Table 2. 
 
Table 2 - Baseline characteristics of patients admitted with hyponatremia 
 mean SD 
age (years) 72.8  15.8 
systolic BP (mmHg) 147.1   28.8 
diastolic BP (mmHg) 77.8  13.2 
serum sodium (mmol/l) 120.9  7.6 
serum potassium (mmol/l) 4.0  0.9 
hemoglobin (mmol/l) 7.6  1.4 
hematocrit (%) 35.0  6.5 
albumin (g/l) 33.4  6.0 
 median range 
stay in hospital (days) 7.5  3-21 
WBC (Tsd./µl) 10.4 4.6-22.7 
CRP (mg/l) 8.8 1-248 
BMI (kg/m2)  25.5 20-40 
serum creatinine (µmol/l) 87.2 20.8-834 
serum osmolality (mOsm/kg) 260.5 218-404 
coin test results (sec) 70.0 20-180 
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female 
64 % 
male 
36 % 
Figure 3 - Distribution of patients with hyponatremia according to sex  
 
 
 
 Hyponatremia has a female predominance  
 
The most frequent age group in both genders was >70 years (n= 33, 66 %) with 
female to male ratio 3.1:1 (Table 3). There is significant relationship between age 
and sex as most of patients between 50 and 70 years were males and most of 
patients >70 years were females (P= 0.042). 
 
Table 3 - Distribution of patients with hyponatremia by age and sex 
 
 
 
 
 
 
 
age groups female % male % total 
<50 years 4 50.0 4 50.0 8 
50-70 years 3 33.3 6 66.7 9 
>70 years 25 75.8 8 24.2 33 
total 32 64.0 18 36.0 50 
Hyponatremia is more frequent in older population >70 years, three-fourths of them are females.  
with P= 0.042 
 
5.2 Factors affecting the length of stay in hospital (LOS) 
The stay in hospital ranged from 3 to 21 days with a median 7.5 days. We have 
found an inverse correlation of LOS with albumin, hemoglobin and a positive 
correlation with age, white blood cells count, and low attention level. Interestingly, 
there was no significant relationship between serum sodium concentration and LOS 
(the baseline characteristics and their relation to LOS are given in Table 4). 
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Table 4 - Baseline characteristics of patients admitted with hyponatremia and their 
relation to LOS (n= 50) 
 Mean sig. relationship correlation 
age (years) 72.8 P= 0.046 0.28 
systolic BP (mmHg) 147.1  P= 0.589 –0.08 
diastolic BP (mmHg) 77.8 P= 0.807 0.03 
s. sodium (mmol/l) 120.9 P= 0.212 –0.18 
s. potassium (mmol/l) 4.0 P= 0.803 –0.04 
hemoglobin (mmol/l) 7.6 P= 0.035 –0.30 
hematocrit (%) 35.0 P= 0.061 –0.27 
albumin (g/l) 33.4 P<0.01 –0.55 
 Median   
WBC (Tsd./µl) 10.4 P= 0.012 0.35 
CRP (mg/l) 8.8 P=0.546 0.08 
BMI (kg/m2)  25.5 P= 0.101 –0.23 
s. creatinine (µmol/l) 87.2 P= 0.200 –0.18 
s. osmolality (mOsm/kg) 260.5 P= 0.599 –0.08 
coin test results (sec) 70.0 P= 0.016 0.34 
Non-Parametric test (Spearman test) showed significant correlation between age, hemoglobin, 
albumin, WBC, low attention level and LOS 
There was no significant relationship between serum sodium concentration and LOS 
 
 
Figure 4 - Correlations between serum albumin, hemoglobin,  age, WBC, low 
attention level (coin test) and LOS 
Panel A 
 
Panel B 
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Panel C 
 
 
Panel D 
 
 
Panel E 
 
 
 
There was statically significant negative correlation between LOS and serum albumin, hemoglobin 
and statically significant positive correlation between LOS and patients age, WBC count, and low 
attention level  
 
5.3. Patients distribution according to epidemiological, clinical and paraclinical 
parameters 
The most frequent type of hyponatremia is hypovolemic hyponatremia (n= 24, 48 %) 
followed by euvolemic (n= 17, 34 %) and hypervolemic hyonatremia (n= 9, 18 %). 
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Figure 5 - Distribution of patients with hyponatremia according to volume status  
 
 Nearly half of the patients (n= 24, 48 %) were hypovolemic, followed by euvolemic and hypervolemic 
subjects 
 
The minimum sodium level was 104 mmol/l, most of patient were with sodium ≤120 
mmol/l or 126-130 mmol/l (40 %, 40 %), respectively. The level of sodium is also 
significantly related to volume status in our study as most of patients with 
hypovolemia and hypervolemia with sodium level (126-130 mmol/l), while most of 
patients with euvolemia with sodium level ≤120 mmol/l, (P= 0.03) (Table 5). 
 
 
Table 5 - Distribution of patients with hyponatremia according to sodium levels 
sodium level 
(mmol/l) 
hypovolemia euvolemia hypervolemia total % 
≤120 8 9 3 20 40.0 
121-125 4 6 0 10 20.0 
126-130 12 2 6 20 40.0 
total 24 17 9 50 100.0 
Half of patients with hypovolemia and two thirds of patients with hypervolemia having sodium level 
(126-130 mmol/l), while more than half of patients with euvolemia having sodium level ≤120 mmol/l, 
(P= 0.03) 
 
The median BMI was 25.5 kg/m2, the minimum BMI was 20 kg/m2, while maximum 
BMI was 40 kg/m2. About half of the patients with hyponatremia with normal BMI 
(Table 6). 
Of the patients, 46 (92 %) presented with chronic hyponatermia while in 4 patients, 
(8 %) hyponatremia was of acute onset (two patients due to gastroenteritis, one 
     Results 
 
  
31 
 
4 
46 
acute
chronic
patient with newly prescribed thiazide diuretics in addition to previous ACE inhibitor 
and beta blockers treatment and one patient after resection of a pituitary 
macroadenoma) (Figure 6). In 30 patients (60 %), the diagnosis of hyponatremia 
was established for the first time while in 20 patients (40 %) hyponatremia had been 
found at an earlier occasion as pre-existed symptomatic or subtle hyponatremia.  
 
 
 
Figure 6 - Distribution of patients according to the onset of hyponatremia  
 
 
46 (92 %) of patients with hyponatremia have a chronic onset 
 
The Less specific symptoms like fatigue, loss of appetite, nausea, vomiting are 
frequently founded in patients with hyponatremia, only 3 patients were 
asymptomatic. Low attention level sometimes was difficult to decide as symptom if 
we took in consideration that most of patients >70 years and part of them with 
dementia (already diagnosed or as defined by mini mental test), additionally some 
symptoms especially nonspecific non neurological symptoms were difficult to be 
attributed to hyponatremia, they could be part of the cause more than hyponatremia 
per se. There is only significant relationship between nausea and onset of 
Table 6 - Distribution of patients with hyponatremia according to BMI 
BMI (kg/m2) frequency % 
18.5-24.9 24 48.0 
25-29.9 17 34.0 
≥30 9 18.0 
total 50 100.0 
Nearly half of patients with hyponatremia having a normal body weight 
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hyponatremia as all patients with acute onset have nausea and less than half of 
patients with chronic onset (47.8 %) have nausea (Figure 7). 
 
Figure 7 - Frequency of symptoms in patients with hyponatremia 
 
Less specific non neurological symptoms are more frequent in hyponatremic patients 
 
5.4. Risk factors 
Hypertension is the most frequent risk factor associated with hyponatremia followed 
by diabetes mellitus and renal failure. 
 
Table 7 - Frequency of risk factors in patients with hyponatremia 
risk factors frequency % 
arterial hypertension 38 76.0 
diabetes mellitus 20 40.0 
renal failure 18 36.0 
congestive heart failure 9 18.0 
pneumonia 5 10.0 
Hypertension is the most frequent comorbidity associated with hyponatremia  
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5.5. Etiologies of hyponatremia 
Diuretics combined with ACE inhibitors, ARA II, and or BB was the most common 
cause of hyponatermia was found in more than half of the patients.  
Other drugs included AVP high dose in two patients, antidepressants; mirtazapin and 
citalopram in two patients plus ARA II (valsartan) in one of them, ACE inhibitor and 
beta blockers in two patients, antipsychotics; quetiapin and metformin in one patient 
and antiepileptic; carbamazepin and ACE inhibitor (lisinopril) in one patient (Figure 
8). Out the 29 patients with hyponatremia due to diuretic therapy, 19 (65 %) on 
diuretic were females. 
 
Figure 8 - Frequency of possible causes in patients with hyponatremia  
 
In more than half of the patients the possible cause of hyponatremia is diuretics + RAAS 
Abbreviations: RAAS: renin angiotensin aldosterone affecting drugs, GI: gastrointestinal, CRF: 
chronic renal failure 
 
 
In most of the patients (58 %), the cause of hyponatremia is likely multifactorial 
although some conditions may be leading or more dominant than others (Table 8). 
 
 
     Results 
 
  
34 
 
Table 8 - Distribution of patients with hyponatremia according to the number of  
possible causes 
cause frequency % 
one cause 21 42.0 
two causes 24 48.0 
three causes 5 10.0 
total 50 100 
Hyponatremia is multifactorial in more than half of patients 
 
 
Interestingly, most patients had been admitted in summer (n= 19, 38 %), followed by 
spring (n= 14, 28 %), autumn (n= 10, 20 %), and in winter (n= 7, 14 %). In summer, 
most of the patients were admitted because of hypovolemia (n= 11, 57.9 %), (n= 8, 
42.1 %) were on diuretics and RAAS inhibitors. Most of them were female (n= 14, 
73.7 %), 13 of them were older than 70 years (68.4 %). 
5.6. Volume Status and etiology 
All of patients with gastrointestinal loss and inadequate salt and water intake as the 
main etiology are hypovolemic, all of patients with other drugs are euvolemic and all 
of CHF are hypervolemic. Most of patients with SIADH are euvolemic and with 
hyperglycemia are hypovolemic. Patients who are using diuretics or diuretics + 
RAAS affecting drugs either hypovolemic or euvolemic. Less common causes 
include; one case due to glucocorticoid deficiency which was hypovolemic, one case 
due to polydipsia which was euvolemic, and one case due to chronic renal failure 
was hypervolemic. There is significant relationship between volume status and 
etiology (P<0.01). 
 
 
 
 
 
     Results 
 
  
35 
 
4 
2 
7 
1 
1 
8 
5 
1 
4 
5 
1 
8 
0 2 4 6 8 10 12 14
GI loss
decreased water and salt intake
diuretics + RAAS affecting drugs
diuretics alone
other drugs
SIADH
heart failure
hyperglycemia
CRF
polydepsia
glucocorticoid deficiency
frequency 
hypovolemia
euvolemia
hypervolemia
Table 9 - Distribution of patients by volume status and main etiology 
etiology hypovolemia euvolemia hypervolemia 
 
total 
 n % n % n % n % 
diuretics + RAAS drugs 7 29.2 5 29.4 0 0.0 12 24.0 
CHF 0 0.0 0 0.0 8 88.9 8 16.0 
hyperglycemia 8 33.3 1 5.9 0 0.0 9 18.0 
decrease water intake 2 8.3 0 0.0 0 0.0 2 4.0 
other drugs 0 0.0 4 23.5 0 0.0 4 8.0 
SIADH 1 4.2 5 29.4 0 0.0 6 12.0 
gastrointestinal loss 4 16.7 0 0.0 0 0.0 4 8.0 
diuretics 1 4.2 1 5.9 0 0.0 2 4.0 
less common causes 1 4.2 1 5.9 1 11.1 3 6.0 
total 24 100 17 100 9 100 50 100 
*Abbreviations: RAAS: renin angiotensin aldosterone affecting drugs, CHF: congestive heart failure, 
SIADH: syndrome of inappropriate antidiuretic hormone 
**There is significant relationship between volume status and etiology (P<0.01) 
 
There is significant relationship between volume status and etiology P= 0.00 as all of patients with 
CHF, GI loss, other drugs are hypervolemic, hypovolemic and euvolemic, respectively. Most of 
patients with SIADH, hyperglycemia  are euvolemic, hypovolemic, respectively 
 
Figure 9 - Frequency of main causes according to volume status 
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5.7. Hematological, urinary and BIS parameters distribution by volume status 
In our study we studied the relationship between several hematological, urinary 
indices in addition to BIS indices and volume status.  We found that creatinine, urea, 
and uric acid were significantly higher in hypervolemic hyponatremia followed by 
hypovolemic hyponatremia and they were lowest in euvolemic hyponatremia. Serum 
osmolality was the lowest in euvolemia reflecting the lowest sodium concentration in 
blood in this group with a mean of 116.8 mmol/l in comparison with other groups. 
Sodium in urine is the lowest in hypervolemic hyponatremia (as most of cases due to 
HF) which also reflected by elevation of SUSPPUP. Serum renin and aldosterone 
are clearly elevated in hypervolemic and hypovolemic hyponatremia. Serum albumin 
concentration and hematocrit were clearly reduced in hypervolemic hyponatremia, 
while NT-proBNP is significantly higher in hypervolamic hyponatremia in comparison 
to the other etiologic groups reflecting the dilutional status and volume overload. BIS 
was corresponding significantly with clinical diagnosis in our study (Table 10, 11).  
 
Table 10 - Means of hematological, urinary and BIS parameters by volume status 
 hypovolemia euvolemia hypervolemia P-value 
 
serum sodium (mmol/l) 
120.2 
±7.6 
116.8 
±7.1 
124.1 
±6.5 
0.066 
urinary osmolality 
(mOsm/kg) 
327.7 
±126.7 
376.9 
±120.7 
314.1 
±154.8 
0.285 
uric acid (µmol/l) 
 
348.6 
±141.9 
246.0 
±116.2 
530.3 
±166.5 
0.001 
albumin(g/l) 
32.7 
±4.7 
34.6 
±7.4 
30.1 
±4.7 
0.256 
serum potassium 
(mmol/l) 
3.8 
±0.9 
4.0 
±0.7 
3.7 
±0.5 
0.534 
hematocrit (%) 
33.7 
±5.6 
33.7 
±4.2 
30.3 
±4.8 
0.265 
overhydration (L) 
–0.6 
± 1.2 
–0.26 
± 1.2 
3.2 
± 1.2 
0.002 
*Only cases with hypotonic hyponatremia were included 
**Uric acid and BIS were corresponding significantly with clinical diagnosis in our study 
Statistical significance was determined by parametric testing, using Anova test. P<0.05 was 
considered statistically significant 
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Table 11 - Medians of hematological and urinary parameters by volume status 
 hypovolemia euvolemia hypervolemia P-value 
 
urea (mmol/l) 
5.5 
(2.3-13.1) 
3.7 
(0.94-12.4) 
14.8 
(4.7-23.0) 
0.002 
urinary sodium 
(mmol/l) 
52.5 
(24-253) 
51.5 
(9-156) 
17.5 
(8-140) 
0.013 
creatinine (µmol/l) 
90.2 
(49.0-169.0) 
63.4 
(20.8-140.0) 
133.0 
(55.4-834.0) 
0.013 
serum osmolality 
(mOsm/kg)  
(mOsm/kg) 
(mOsm/kg) 
(mOsm/kg) 
258.0 
(218-269) 
249.5 
(222-275) 
273.0 
(249-283) 
0.004 
NT-proBNP (pg/ml) 
529.0 
(45-7391) 
492.0 
(42-3623) 
19282.0 
(1638-111323) 
0.000 
aldosterone (pmol/l) 
271.0 
(30-3452) 
171.5 
(38-1203) 
191.5 
(93-11638) 
0.638 
renin (pmol/l/hr) 
34.1 
(1.0-725.0) 
12.7 
(3.9-200.0) 
42.5 
(2.3-819.0) 
0.550 
SUSPPUP 
4.6 
(1.8-11.5) 
4.3 
(0.5-18.6) 
15.5 
(0.55-23.6) 
0.011 
*Urea, urinary sodium, creatinine, serum osmolality, NT-proBNP, and SUSPPUP were 
corresponding significantly with clinical diagnosis in our study 
**Range is illustrated between brackets 
***Abbreviations: SUSPPUP=Serum sodium to urinary sodium to (serum potassium)
 2
 to urinary 
potassium 
****Statistical significance was determined by non-parametric testing, using the Kruskal–Wallis test. 
P<0.05 was considered statistically significant
 
 
 
5.8. Hematological, urinary parameters distribution by etiologies 
 
In our study, we compared different hematological and urinary parameters between 
the etiologies of hyponatremia. Serum sodium, plasma osmolality, uric acid, urea 
and creatinine are the lowest in patients with SIADH. Hematocrit, urinary and plasma 
osmolality are the highest in hyperglycemia. Urinary sodium is the lowest in CHF (in 
all cases below 30 mmol/l) with elevation of SUSPPUP. Serum creatinine is the 
highest in hyperglycemia followed by CHF. Urinary and serum potassium are the 
lowest in GI loss and SUSPPUP is the highest in CHF as compared to other causes. 
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Figure 10 – Medians/ means of hematological, urinary and BIS parameters 
distribution by volume status 
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Table 12 - The relationship between means of paraclinical parameters and etiologies of hyponatremia 
 GI loss decrease 
water 
intake 
diuretics diuretics
+ RAAS 
drugs 
other 
drugs 
SIADH heart 
failure 
hyperg-
lycemia 
less 
common 
causes 
P-value 
serum sodium 
(mmol/l) 
121.2 
± 4.6 
119.0 
± 12.7 
122.0 
± 7.1 
118.6 
± 7.5 
118.7 
± 7.4 
113.5 
± 9.1 
123.7 
± 6.9 
127.0 
± 3.4 
124.3 
± 2.3 
0.038 
urinary osmolality 
(mOsm/kg) 
300.7 
± 185 
113 
± 0.0 
412 
± 55.1 
364.9 
± 94.6 
337.2 
± 79.2 
404.5 
± 165.3 
334.9 
± 154.8 
550.3 
± 119.3 
245.3 
± 90.3 
0.005 
uric acid (µmol/l) 
371.5 
± 200.8 
429.0 
± 243.3 
448.0 
± 96.2 
331.5 
± 99.2 
221.5 
± 50.8 
170.8 
± 75.9 
561.0 
± 166.2 
404.0 
± 165.2 
282.3 
± 100.4 
0.002 
albumin (g/l) 
33.5 
± 6.1 
28.9 
± 0.28 
19.4 
± 9.0 
36.2 
± 4.0 
37.0 
± 2.4 
32.3 
± 5.5 
30.1 
± 4.7 
35.1 
± 5.5 
36.9 
± 5.5 
0.003 
serum potassium 
(mmol/l) 
2.87 
± 7.0 
4.6 
± 0.2 
4.0 
± 0.1 
4.0 
± 0.9 
4.1 
± 1.2 
4.0 
± 0.3 
3.7 
± 0.5 
4.7 
± 1.0 
3.7 
± 0 .5 
0.026 
hematocrit (%) 
35.2 
± 5.4 
25.5 
± 0.7 
29.0 
±1.4 
34.7 
± 5.4 
36.2 
± 1.3 
32.8 
± 4.2 
30.9 
± 4.8 
44.0 
± 4.6 
32.0 
± 5.3 
0.000 
Serum sodium and uric acid are the lowest in patients with SIADH, urine osmolality is the highest in hyperglycemia, serum potassium is the lowest in GI 
loss 
Abbreviations: GI loss: gastrointestinal loss, RAAS: renin angiotensin aldosterone affecting drugs 
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Table 13 - The relationship between medians of paraclinical parameters and etiologies of hyponatremia 
 GI loss decrease 
water 
intake 
diuretics Diuretics + 
RAAS 
drugs 
drugs 
other 
drugs 
SIADH heart 
failure 
hypergl- 
ycemia 
less 
common 
causes 
P-
value 
urinary sodium 
(mmol/l) 
57.0 
(24-82) 
40.0 
(25-55) 
60.0 
(43-77) 
50.0 
(32-253) 
52.5 
(47-117) 
62.0 
(22-156) 
16.0 
(8-28) 
38.0 
(5-95) 
29.0 
(9-140) 
0.057 
urea (mmol/l) 
4.6 
(2.6-7.1) 
9.5 
(5.9-13.1) 
5.3 
(5.2-5.5) 
4.6 
(2.3-12.4) 
4.2 
(2.5-5.7) 
2.0 
(0.9-3.7) 
12.4 
(4.7-22.2) 
9.7 
(2.4-19.2) 
9.1 
(3.2-23.0) 
0.019 
serum creatinine 
(µmol/l) 
84.4 
(49-169) 
96.5 
(94.5-98.5) 
87.7 
(64.4-111) 
90.2 
(60.5-140) 
63.9 
(52.2-86.2) 
49.6 
(20.8-61.9) 
132.5 
(55.4-185) 
171.0 
(62.8-250) 
96.0 
(44.8-834) 
0.012 
NT-proBNP 
(pg/ml) 
340.0 
(111-900) 
1219.5 
(603-1836) 
611.0 
(128-1094) 
885.0 
(45-7391) 
464.5 
(79-1135) 
355.5 
(236-3623) 
8605.5 
(163-12500) 
192.0 
(15-1104) 
76.7 
(42-111323) 
0.008 
plasma osmolality 
(mOsm/kg) 
260.5 
(244-270) 
261.5 
(227-296) 
264.0 
(253-275) 
255.5 
(218-269) 
252.0 
(228-261) 
239.5 
(222-280) 
272.5 
(249-280) 
302.5 
(285-404) 
260.0 
(256-283) 
0.000 
urinary potassium 
(mmol/l) 
10.0 
(9-26) 
28.8 
(9-49) 
22.4 
(21-24) 
33.3 
(8-76) 
26.9 
(24-46) 
23.9 
(12-58) 
20.0 
(15-60) 
22.5 
(9-32) 
10.2 
(4-11) 
0.28 
SUSPPUP 
5.0 
(2.6-9.8) 
3.4 
(2-4.9) 
3.2 
(1.9-4.4) 
3.3 
(0.8-18.6) 
5.0 
(1.1-7.8) 
5.0 
(0.5-9.5) 
15.9 
(9.5-23.6) 
2.6 
(1.9-15) 
4.2 
(0.5-4.3) 
0.032 
TTKG 
4.3 
(4.2-6.6) 
4.0 
(4.0-4.0) 
3.6 
(2.9-4.4) 
6.0 
(1.6-18.9) 
6.3 
(3.3-7.9) 
3.9 
(1.4-5.9) 
4.9 
(2.3-13.8) 
2.5 
(2.1-3.7) 
3.7 
(0.9-4.4) 
0.126
renin (pmol/l/hr) 
20.0 
1.0-70.4 
40.3 
7.9-72.7 
390.5 
22.0-581.0 
16.9 
1.7-725.0 
8.1 
3.9-19.5 
12.9 
3.9-38.3 
48.8 
9.0-819 
50.7 
8.3-348.0 
30.0 
2.3-196.0 
0.338 
aldosterone 
(pmol/l) 
251 
90-285 
87 
30-144 
1177.5 
654-1701 
271 
85-3452 
159 
116-198 
175.5 
38-1203 
218 
93-11638 
288.5 
102-802 
184 
165-461 
0.464 
plasma osmolality, serum creatinine and urea are the highest in hyperglycemia and CHF and are the lowest in SIADH, SUSPPUP is the highest and urinary 
sodium is the lowest in CHF as compared to other causes. GI loss: gastrointestinal loss, RAAS: renin angiotensin aldosterone affecting drugs, SUSPPUP: 
Serum sodium to urinary sodium to (serum potassium)
 2
 to urinary potassium 
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5.8. Important clinical and paraclinical findings before and after therapy 
The mean/median of BP, creatinine, urea, uric acid, SUSPPUP, aldosterone, and 
renin were higher in patients with hyponatremia before than after therapy, while the 
mean /median of serum osmolality, serum sodium, attention level were lower, with 
significant P value <0.05. 
 
 
Table 14 - Comparison between important clinical and paraclinical findings before 
and after therapy of the patients with hyponatremia 
 
normally distributed 
values 
baseline after intervention 
P 
value 
 mean SD mean SD  
uric acid (µmol/l) 350.1  162.3 303.7  143 0.021 
serum sodium(mmol/l)  120.9  7.6 134.5  4.2 0.000 
s. potassium (mmol/l) 4.04  0.9 3.98  0.7 0.647 
u. osmolality (mOsm/kg)  387.6  161.7 367.7  146 0.456 
a. systole (mmHg) 147.1  28.8 131.4  14.7 0.000 
a. diastole (mmHg) 77.8  13.2 73.8  8.7 0.034 
coin test (sec) 76.2  35.1 71.2  34.7 0.012 
non-normally 
distributed values 
median range median range 
P 
value 
s. creatinine (µmol/l) 87.2 20.8-834.0 82.3 43.9-845.0 0.020 
urea (mmol/l) 5.2 0.9-23 4.2 1.0-23.1 0.001 
s. osmolality (mOsm/kg)   260.5 218-404 285 267-324 0.000 
u. sodium (mmol/l) 47 5-253 77.5 10-204 0.000 
u. potassium (mmol/l)  23.1 4.0-76.0 24.4 5.6-74.0 0.145 
SUSPPUP 4.4 0.54-23.6 2.7 0.5-13.7 0.041 
TTKG 4.1 0.9-18.9 4.7 2.1-14.0 0.128 
NT-proBNP (pg/ml) 603 15-111323 514 2-11230 0.828 
aldosterone (pmol/l) 234.5 30-1638 103 4-2223 0.000 
renin (pmol/l/hr) 20 1-819 13.2 1-505 0.007 
The following parameters: BP, creatinine, urea, uric acid, urinary sodium, SUSPPUP, aldosterone, 
renin, serum osmolality, serum sodium, attention level are changed significantly after therapy, P< 0.05 
Abbreviations: s.: serum, u.: urinary, a: arterial, SUSPPUP: serum sodium to urinary sodium to (serum 
potassium)
 2
 to urinary potassium, TTK: trans-tubular potassium gradient 
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Discussion 
Hyponatremia is one of the most common electrolyte and water balance disorders 
the physician faces in hospital. Although in last years, development in approaches of 
the diagnosis and treatment of hyponatremia was seen, it still poses diagnostic and 
therapeutic challenges. However, little is known about the etiology of hyponatremia 
among patients in Mecklenburg-Western Pommeranian hospitals and the best 
parameters help to establish a diagnosis. 
Many studies showed female predominance in patients with hyponatremia while in 
others, there is male predominance. The mean age of patients in our study was 72.8 
± 15.8 years (range 35-93 years) with a female predominance (n=32, 64 %). The 
higher incidence of hyponatremia in elderly patients in our study could be attributed 
to several factors such as decreased glomerular filtration rate, presence of 
comorbidities, and polypharmacy leading to impairment in water and electrolyte 
hemostasis and the response to dietary and environmental factors (Fregan et al. 
2005; Beck et al. 2000; Chua et al. 2007). It is nearly similar to a study involving two 
Swiss academic centres and included patients with profound hyponatremia (sodium 
<125 mmol/l), the median age of the participants was 71 years (interquartile range 
(IQR) 60-80), (65 %) were female (Nigro et al. 2015). In another study, there was 
also a female predominance (55 %) (Rao et al. 2010). The mean age of patients in 
our study was higher than what reported in an Indian study involving ICU patients 
(60.4 ± 17.2 years) but with similarly female predominance (56.5 %) (Padhi et al. 
2014). However, in another two studies there was a male predominance (51.2 %, 
62.7 %) (Coenraad et al. 2007; Chatterjee et al. 2012), respectively. This variation 
can be explained by the inclusion criteria in our study (serum sodium ≤130 mmol/l), 
study population and specificity of each department. 
In our study, the mean sodium level on admission was 120.9 ± 7.6 mmol/l, which 
was nearly similar to Nigro et al. (2015) with a mean serum sodium concentration of 
120 mmol/l and lower than Coenraad et al. (2007) who observed 128 mmol/l in his 
cohort. 
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Many studies showed a prolongation of hospital stay in patients with hyponatremia in 
comparison with normonatremic patients and included patients admitted to internal 
medicine or neurosurgical departments or concerned specific diseases such as 
pneumonia, heart failure or cancer (Garcia et al. 1994; Gill et al. 2006;  Zilberberg 
et al. 2008;  Ali  et al. 2016; Marco et al. 2013; Zanocchi et al. 2002; Scherlock et al. 
2009; Hennrikus et al. 2015; Brouns et al. 2014; Conway et al. 2014; Callahan et al. 
2009). However, one study was not able to prove this difference in the LOS between 
patients with or without hyponatremia (Lim & Yap, 2001). It focussed on geriatric 
patients, paying attention to the fact that the people are elderly, fragile and 
hospitalized principally for acute medical conditions.  
The median stay of patients with hyponatremia was 7.5 days in our study which was 
similar to patients with moderate-to-severe hyponatremia as compared to other 
studies (Callahan et al. 2009; Zilberberg et al. BMC Pulm Med 2008; Zilberberg et al. 
Curr Med Res Opin 2008). However, in one study the LOS was much higher and 
compromised 16 ± 12 days (Gill et al. 2006). There was no clear reason for 
prolonged LOS in the last study even if we take into consideration that the hospital-
based studies involved severe hyponatremic patients with a serum sodium 
concentration <125 mmol/l. It should be emphasized that the mean LOS of randomly 
chosen normonatremic patients was also long in this analysis (13 ± 11 days). 
According to our knowledge, there are few if no studies which illustrate the factors, 
affecting LOS in patients with hyponatremia and if the level of serum sodium per se 
mediates the effect on LOS or whether there are other factors such as demographic 
factors, other laboratory parameters or comorbidities to play a role. 
In our study (Table 4), there was no significant relation between serum sodium 
concentrations and LOS, which was similarly found by a recent study and a meta-
analysis (Callahn et al. 2009; Corona et al. 2016). The stay in hospital in our study 
was strongly negatively correlated with serum albumin and also to a lesser extent 
with hemoglobin and positively correlated with patient‘s age, WBC, and low attention 
level. 
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One important such factor which was associated with LOS in our hyponatremic 
patients was the concentration of serum albumin which showed a medium but 
strongly significant correlation with LOS. Serum albumin concentrations serve as a 
marker of a patient's nutritional state, acute and chronic inflammatory responses. 
Besides malnutrition-inflammation complex syndrome there are other factors playing 
a role in development of hypoalbuminemia such as hemodilution, liver dysfunction, 
increased transcapillary escape rate, protein-losing enteropathy and renal loss 
(Arques & Ambrosi, 2011; Haller, 2005). Interestingly, hypoalbuminemia was found 
to be a predictor of neurological manifestations of hyponatremia and the only 
independent risk factor for death (Shapiro et al. 2010). Also, hypoalbuminemia was 
an independent risk factor for LOS and or mortality in patients with COPD, heart 
failure, end stage renal disease ESRD as well as elderly patients (Zanocchi et al. 
2002; Wang et al. 2014; Martín-Sánchez et al. 2016). Additionally, it is not 
uncommon to find in patients with nutritional deficiency due to chronic diseases 
electrolytes, including sodium and vitamins depletion beside hypoalbuminemia.  
Albumin is an important transporter for non-water-soluble protein-bound drugs and 
toxins in addition to various substances, fatty acids, metals, ions, and hormones. 
Presence of drugs with high binding characteristics to plasma proteins allows for 
higher drug levels and more rapid hepatic metabolism. Hypoalbuminemia is linked 
with adverse outcome in patients with end stage renal diseases and hepatic 
insufficiency could be attributed to the increase in the free albumin-bound toxins 
(Meijers et al. 2008).  Additionally, albumin plays an important role as circulating 
antioxidant, about 80 % of the thiol groups in blood are derived from albumin 
molecule. The reduction of blood thiol content aggravates oxidative stress (Anraku et 
al. 2011). Hypoalbuminemia favours also volume overload and diuretic resistance. 
In our study, anemia was one of the factors associated with LOS in patients with 
hyponatremia which was mentioned as one of the parameters that increased hospital 
stay by internal medicine patients in general or patients with specific diseases such 
as heart failure or cancer (Nathavitharana et al. 2012; Lin et al. 2013; Martín-
Sánchez et al. 2016; Shayne et al. 2013). Infection reflected by increased WBC also 
affects LOS which was similarly found in cancer patients (Shayne et al. 2013). 
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In our study (Figure 5), nearly half of the patients 24 (48 %) were hypovolemic, 
followed by euvolemic 17 (34 %) and hypervolemic subjects 9 (18 %). This is nearly 
similar to what was found by other studies (Coenraad et al. 2003; Hochman et al. 
1989), but different from a study in patients in department of internal medicine as 
hypervolemic hyponatremia (n= 41, 49.4 %) associated with liver cirrhosis and 
hearth failure was most frequent (Rudnay et al. 2013) and similarly by (Gross et al. 
1988). However, the largest group of hyponatremic patients were euvolemic in two 
other studies carried in internal medicine ward in tertiary care hospital and in critically 
ill patients on intensive care unit ICU (Chatterjee et al. 2012; Padhi et al. 2014). 
The tendency to hyponatremia could be explained also near to old age, to the use of 
thiazide diuretics by patients with thin body composition. In our study about half of 
the patients (48 %) with BMI 18.5-24.9 kg/m2. Several studies mentioned the risk 
factors of thiazide induced hyponatremia TIH like reduced body mass (Sharabi et al. 
2002; Clayton et al. 2006; Chow et al. 2003; Rodenburg et al. 2013). The reason is 
not completely clear; the level of sodium in the plasma is determined by the total 
body water. Thus, its concentration changes significantly in subject with smaller body 
mass and consequently less total body water. Besides, decreased body mass or 
muscle wasting might also signify underlying disease (Abramow & Cogan, 1984). 
46 (92 %) patients were presented with chronic hyponatermia, while in 4 patients (8 
%) hyponatremia was of acute onset (two patients due to gastroenteritis, one patient 
with newly prescribed thiazide diuretics in addition to previous ACE inhibitors and BB 
therapy and one patient presented after pituitary macroadenoma resection). 
In 30 (60 %) of patients the diagnosis of hyponatremia was established for the first 
time while in 20 (40 %) they were already diagnosed before with pre-existing 
symptomatic or subtle hyponatremia. 
(Figure 7) illustrates frequency of symptoms in patients with hyponatremia from the 
most frequent to less frequent. Less specific symptoms like fatigue, loss of appetite, 
nausea, vomiting are more frequent with the following frequencies, fatigue (n= 38, 76 
%), loss of appetite (n= 31, 62 %), nausea (n= 26, 52 %), vomiting (n= 20, 40 %). 
This findings are comparable to Nigro et al. 2015 study, clinical symptoms were 
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generalized weakness (n= 205, 69 %), fatigue (n= 175, 59 %), nausea (n= 130, 44 
%), acute vomiting (n= 91, 30 %). More severe symptoms such as acute epileptic 
seizures were identified in 2 (4 %) participants which was similarly found by Nigro et 
al. (2015). A low attention level was sometimes difficult to be interpreted as a 
symptom if we took in consideration that most of patients were over 70 years of age. 
In addition, some symptoms, incl. loss of appetite, nausea and vomiting, were 
difficult to be attributed to hyponatremia because they could well have been part of 
the disease complex causing hyponatremia rather than a consequence of it per se. 
There is only significant relationship between nausea and onset of hyponatremia as 
all patients with acute onset have nausea and less than half of patients with chronic 
onset (47.8 %) have nausea. Following Chatterjee et al. 2012, a large fraction of 
cases (48.2 %) are asymptomatic. In our study was not the same, only 6 % were 
asymptomatic. This could be explained by the inclusion criteria in our study with 
sodium concentration ≤130 mmol/l while by Chatterjee et al. <135 mmol/l. 
In our study arterial hypertension was the most common comorbidity associated with 
hyponatremia (76 %) followed by DM (40 %), renal failure (36 %), congestive heart 
failure (18 %), and pneumonia (10 %) (Table 7). By (Kayar, 2016), comorbidities of 
the patients with hyponatremia were hypertension (73.8 %) followed by diabetes 
mellitus (52.2 %), (49.4 %) had chronic kidney disease and (34 %) had congestive 
heart failure. Similarly, the common co-morbid conditions were hypertension then 
diabetes mellitus by (Rao et al. 2010; Mohan et al. 2013). Due to Nigro et al. 2015, 
the most common comorbidities were hypertension (n= 199, 67 %), pulmonary 
disease (n= 82, 28 %), chronic renal failure (n= 64, 21 %) and congestive heart 
failure (n= 44, 15 %). 
The use of diuretics in combination with inhibitors of the renin-angiotensin system 
was one of the most common clinical scenarios promoting development of 
hyponatremia in our study (Figure 8). The concept of promoting natriuresis together 
with blockade of aldosterone secretion or action was implemented in more than a 
half of the patients (52 %), and are in concordance with the observation of others 
who associated diuretics with hyponatremia in half the portion of patients (Al 
Barqawie et al. 2007), two-third (Kennedy et al. 1978) and even three-fourth of cases 
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(Cumming et al. 2014). The importance of thiazide-induced hyponatremia (TIH) is 
reemerging because thiazide diuretic prescription seems to be increasing after 
appearance of evidence-based statements on thiazides as a possible first-line 
treatment in essential hypertension (Mancia et al. 2007). In an Indian study, the most 
common causes of hyponatremia included the syndrome of inappropriate antidiuretic 
hormone secretion (SIADH) and use of diuretics in elderly hospitalized patients (Rao 
et al. 2010). This was differing from other studies in which SIADH was the most 
common suspected cause (by Liamis et al. 2007; Padhi et al. 2014; Shapiro et al. 
2010). Of note, gastrointestinal fluid loss may also be a main cause of hyponatremia 
in a selected patient cohort (Coenraad et al. 2003; Chatterjee et al. 2012). These 
differences can be explained by the heterogeneity of patient populations and 
inclusion criteria. In addition, study results obtained in entire hospital populations 
including intensive care units and neurosurgery departments may not be fully 
comparable to our analysis and those of others. 
Out the 29 patients with hyponatremia due to diuretic therapy (Figure 8), from them 
19 (65 %) were females. This was nearly similar to Al Barqawi. 2007 study, in which 
(60 %) of hyponatremic patients caused by diuretic therapy were female.  
Another two studies have shown that (70 %, 71 %), respectively of their 
hyponatremic patients were female (Sharabi et al. 2002; Ashraf et al. 1981). Similar 
results found by (Fishman et al. 1971; Abramow et al. 1986), the reason is 
questionable but women possibly drink more than men and may develop dilutional 
hyponatremia (Kone et al. 1986), they treated more often with diuretics (Klungel et 
al. 1997) and hence more prone to dilutional hyponatremia and they are more 
symptomatic than men (Ayus et al. 1992). 
There is significant relationship between volume status and etiology P= 0.00.  In 
(Table 9) patients in whom either diuretics alone or in combination with other RAAS 
affecting drugs (total14) 8 were hypovolemic and 6 were euovolemic. This was also 
prescribed by (Guyatt et al. 2008; Hamburger et al. 1981) as diuretics may cause 
normal or mildly increased extracellular fluid volume state. Diuretics alone or in 
combination with other RAAS drugs followed by SIADH are the most common 
causes of euvolemic hyponateremia in our study. Similarly, the most common 
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causes of euvolemic hyponatremia by Runday et al. are SIADH and thiazide 
diuretics therapy. 
In most of the patients (58 %), the cause of hyponatremia was multifactorial (1.68 
causes per patient) although there may be conditions with a more dominant direct 
effect than others. As shown in a cohort of elderly patients with fragility fractures, the 
cause of hyponatremia was assumed to be of multi-factorial in etiology in 73 % of 
cases (Cumming et al. 2014). Likewise, other studies discussed the hyponatremia to 
be of multifactorial origin in 51 % of patients (1.7 etiological factors per patient) by 
(Shapiro et al. 2010), and 54 % (Al Barqawie et al. 2007). 
The relationship between hyponatremia and season was clear in our study whereas 
(n=19, 38 %) of patients had been admitted in summer, most of them due to 
hypovolemia 11/19 (57.9 %), were female 14 (73.7 %) and old age >70 years 13 
(68.4 %).  8 (42.1 %) were using diuretics. An Indian study by Kalaiselvan et al. 2015 
on critically ill patients admitted to ICU due heat related illness especially in summer, 
the most common metabolic abnormality found was hypontremia (75 % of patients). 
Another Indian study by Chatterjee et al. 2012, illustrated increased incidence of 
hyponatremia in the monsoon season. 
The assessment of volume status takes in most guidelines a central role (Verbalis et 
al. 2013; Hoorn et al. 2013; Nagler et al. 2014). In the last European guidelines and 
based on the low sensitivity and specificity of clinical assessments of volume status, 
they used it far down in diagnostic algorithm to make the misclassification less likely 
(Spasovski et al. 2014). However, presence of renal disease and or using of diuretics 
still also affect urine sodium concentration in addition to the possibility of more than 
one cause affecting every classification. Therefore, there is increasingly need to 
improve the classification based on volume status by finding of objective beside 
subjective measures which in many cases are matter of experience. Various indices 
have been used to assess hydration status adjacent to physical examination, 
including change in body weight, hematological indices, urinary indices, BIA and 
cardiovascular indices.  
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In our study we tried to study the relationship between several hematological, urinary 
indices in addition to BIA indices and volume status as illustrated in table (10, 11). 
We found that creatinine, urea, uric acid and plasma osmolality were higher in 
hypervolemic hyponatremia followed by hypovolemic hyponatremia and they were 
lowest in euvolemic hyponatremia, which was similar to Coenraad et al. 2003 study. 
A similar pattern of elevated serum urea, creatinine and uric acid concentrations in 
hyponatremic patients with hypervolemia and normal or slightly decreased 
concentrations in patients with SIADH has been shown by Decaux et al. 1994. 
In addition, there was statically significant relationship between serum creatinine, 
urea, uric acid, plasma osmolality, urinary sodium and volume status which also 
described by Coenraad et al. 2003 study. Elevated concentrations of serum urea, 
creatinine and uric acid confirmed effective circulating volume depletion in 
hypervolemia and hypovolemia. Near normal values for concentrations of serum 
urea, creatinine, uric acid confirmed the normovolemic status of patients with 
euvolemia. Serum potassium, urine osmolality were statistically not significantly 
related to volume status, which is also similar to Coenraad study.  
  
However, serum albumin concentration was clearly reduced in hypervolemic 
patients in comparison to the other etiologic groups, which was mentioned by 
Coenraad study. Similarly, hematocrit was reduced in hypervolemic patients 
reflecting the dilutional status. Although there was clear elevation in serum renin and 
aldosterone in hypervolemic and hypovolemic hyponatremia reflecting effective 
circulating volume depletion and inhibition of renin-aldosterone as a respond to 
water retention in euvolemia such relationship was not statistically significant. This 
could be explained by the need of reliable baseline measurements such as posture 
and using of tourniquet when parameters like hemoglobin, hematocrit, renin, and 
aldosterone are taken for accurate assessment of volume status (Stowasser et al. 
2012; Shirreffs et al. 2003; Kavouras 2002). Additionally, we must take in 
consideration the using of diuretics and RAAS affecting drugs. 
NT-proBNP is significantly higher in hypervolemic hyponatremia. It is worth 
mentioning that another concluded that, NT-proBNP levels of the patients with 
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hypovolemia were significantly lower than the patients with euvolemia study 
(Bunnag et al. 2012), which was not found in our study. 
Plasma osmolality and sodium concentration have also been used to assess 
hydration status. During dehydration, especially during hypertonic hypovolemic 
dehydration from poor fluid intake, both plasma sodium and osmolality are 
significantly elevated. But these parameters also depend on salt intake or loss and 
degree of AVP stimulation. 
Urinary parameters especially USG, urine osmolality and colour are widely used not 
only because they provide correct and rapid information on hydration status, but also 
because they are comparatively easy to measure, however in our study and 
coenraad et al. study urine osmolality was not significantly different between the 
patients. 
There were several studies performed to evaluate bioimpedance spectroscopy role 
in evaluation of hydration status in hemodialysis patients (Garagarzaa et al. 2013; 
Machek et al. 2010) and patients undergo peritoneal dialysis (Siaphi et al. 2011). 
However, there are still studies found clinical judgment guided by a single clinical 
examination were better as multifrequency bioimpedance analysis (Vasko et al. 
2013). In other hand, a few studies were studied the role of bioimpedance 
spectroscopy in the estimation of body fluid status in hyponatremia (Kim et al. 2014; 
Comming et al. 2014; Kose et al. 2015). In these studies, BIS was corresponding 
significantly with clinical diagnosis, which was also founded in our study. 
In our study, we compared different hematological and urinary parameters between 
the causes of hyponatremia. Serum sodium, serum osmolality, uric acid, urea and 
creatinine are the lowest in patients with SIADH followed by other drugs. Hematocrit, 
creatinine, urinary and plasma osmolality are the highest in hyperglycemia as a 
result of osmotic diuresis and subsequently volume depletion. NT-proBNP is the 
highest in HF patients. Sodium in urine is the lowest in HF (less than 30 mmol /l in all 
cases) and SUSPPUP ratio is the highest reflecting activation of renin-angiotensin-
aldosterone system with secondary renal sodium retention despite body volume 
overload. Serum and urinary potassium are the lowest in GI loss. 
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In our study, there is significant increase in serum sodium and consequently serum 
osmolality and significant reduction in creatinine, urea, uric acid, SUSPPUP, 
aldosterone and renin concentrations after therapy of hyponatremia reflecting 
improvement in effective circulating volume (Table 14). Clinical parameters as blood 
pressure and attention level significantly improved after correction of hyponatremia. 
Other parameters such as urinary osmolality, NT-proBNP, and TTKG were not 
significantly changed after therapy. This is comparable to a study by (Coenraad et al. 
2007) in which plasma AVP and ANP concentrations did not change during 
treatment of hyponatremia despite a significant increase in serum osmolality. 
However, there are some limitations of this study. Firstly, the study population was 
recruited from a single department. Secondly, the included population was relatively 
small; therefore, the external validity of our results might be limited. 
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Conclusion 
We infer from our study: 
- Hyponatremia was more common in older people with a mean age of 72.8 ± 15.8 
years. Most of the patients with hyponatremia were of female gender (n= 32, 64 
%). 
- The median stay in hospital of patients with hyponatremia was 7.5 days. 
Interestingly, in our study, there was no significant relation between serum 
sodium concentrations and LOS. In our study, the stay in hospital was strongly 
negatively correlated with serum albumin and also to lesser extent with 
hemoglobin and positively correlated with patient‘s age, WBC, and low attention 
level. 
- 46 (92 %) patients were presented with chronic hyponatremia. Less specific 
symptoms like fatigue, loss of appetite, nausea, vomiting were more frequent. 
- In our study arterial hypertension was the most common comorbidity associated 
with hyponatremia (76 %) followed by DM (40 %), renal failure (36 %), and 
congestive heart failure (18 %). 
- The use of diuretics in combination with inhibitors of the renin-angiotensin- 
aldosterone system was one of the most common clinical scenarios promoting 
development of hyponatremia in our study found in more than half of the patients 
(n= 26, 52 %). 
- In more than half of patients (58 %), the cause of hyponatremia was multifactorial 
(1.68 causes per patient). 
- The relationship between hyponatremia and season was clear in our study since 
38 % of patients had been admitted in summer, most of them due to hypovolemia 
11/19 (57.9 %), were female 14 (73.7 %). 
- There was statically significant relationship between serum creatinine, urea, uric 
acid and volume status. Elevatetion of these parameters confirm effective arterial 
volume depletion in hypervolemia and hypovolemia. Near normal values or even 
lower concentrations confirm normovolemic state. Serum osmolality was the 
lowest in euvolemia reflecting the lowest sodium concentration in blood in this 
group with a mean of 116.8 mmol/l in comparison with other groups. Sodium in 
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urine is the lowest in hypervolemic hyponatremia (as most of cases due to HF). 
Therefore there is elevation of SUSPPUP reflecting activation of renin- 
angiotensin-aldosterone system with secondary renal sodium retention despite 
body volume overload. In addition, NT-pro BNP was significantlyy elevated in 
hypervolemia. 
- Although there was clear elevation in serum renin and aldosterone in 
hypervolemic and hypovolemic hyponatremia, such elevation was not statistically 
significant. 
-  BIS was corresponding significantly with clinical diagnosis and can be used as 
useful diagnostic procedure to reach a diagnosis. 
- In our study, there was a significant increase in serum sodium, serum osmolality 
and significant reduction in creatinine, uric acid, urea, aldosterone, renin, and 
SUSPPUP concentrations after therapy of hyponatremia reflecting improvement 
in effective circulating volume. Clinical parameters like blood pressure and low 
attention level were significantly improved after correction of hyponatremia.
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Theses of Dissertation 
 
- In Mecklenburg-Western Pommerania hyponatremia was more common in older 
people with mean age of 72.8 ± 15.8 years especially females (64 %). The mean 
sodium level was 120.9 ± 7.6 mmol/l. The most frequent type of hyponatremia is 
hypovolemic hyponatremia (48 %). 
 
- The length of stay in hospital of patients with hyponatremia was not related to 
serum sodium concentrations. There are other important factors play a role like 
hypoalbuminemia, anemia, increased age, infection or inflammation, and low 
attention level. 
 
- In more than half of patients (58 %), the cause of hyponatremia was multifactorial 
(1.68 causes per patient). The use of diuretics in combination with inhibitors of 
the renin-angiotensin system was one of the most common clinical scenarios 
promoting development of hyponatremia in our study found in more than half of 
the patients (52 %). 
 
- The relationship between hyponatremia and season was clear in our study since 
38 % of patients had been admitted in summer, most of them due to hypovolemia 
(57.9 %), were female (73.7 %). 
- Serum urea, creatinine, uric acid, serum osmolality, urinary sodium, SUSPPUP, 
NT-proBNP are the best parameters helping in evaluation of volume status. 
Elevated concentrations of serum urea, creatinine, uric acid confirmed effective 
circulating volume depletion in hypervolemia and hypovolemia. Near normal 
values of of these parameters confirmed the normovolemic status. Serum 
osmolality was the lowest in euvolemia reflecting the lowest sodium concentration 
in blood in this group. Sodium in urine is the lowest in hypervolemic hyponatremia 
(as most of cases due to HF). Therefore there is elevation of SUSPPUP reflecting 
activation of renin-angiotensin-aldosterone system with secondary renal sodium 
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retention despite body volume overload. In addition, NT-pro BNP was 
significantly higher in hypervolamic hyponatremia reflecting the dilutional state. 
 
- Although there was clear elevation in serum renin and aldosterone in 
hypervolemic and hypovolemic hyponatremia, such elevation was not statistically 
significant. 
 
- Bioelectrical impedance spectroscopy measurements were corresponding 
significantly with clinically evaluated volume status and can be used as useful 
diagnostic procedure to reach a diagnosis. 
 
- In our study, there was a significant increase in serum sodium, serum osmolality 
and significant reduction in creatinine, uric acid, urea, aldosterone, renin, and 
SUSPPUP (serum sodium to urinary sodium to (serum potassium)² to urinary 
potassium) concentrations after therapy of hyponatremia reflecting improvement 
in effective circulating volume. Clinical parameters like blood pressure and low 
attention level were significantly improved after correction of hyponatremia 
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14.1 Data collection sheet 
 
Causes of disturbances and parameters of the volume status in patients with 
hyponatremia 
 
                                                                                    No. Of questionnaire ………… 
                                                                                    File No. ……………………….. 
 Patient name: ………………………………………………… 
 Date of births: l__l__l l__l__l l__l__l 
 Sex:  □ Male     □Female 
 Height:    l__l__l__l cm     Weight:  l__l__l__l, l__l  kg  
 Date of admission:  l__l__l l__l__l l__l__l 
 Date of discharge:  l__l__l l__l__l l__l__l  
 Type of hyponatremia:       □ Acute (< 48 h)            □ Chronic 
 Hyponatremia diagnosis:  □ First time                    □  Not first time 
 Volume status: 
     □ Hypovolemia           □ Euvolemia                  □ Hypervolemia    
Diagnosis: ………………………………………………………………. 
…………………………………………………………………………….   
 
Etiologie: 
□ Diuretics □ RAAS □ GI fluid loss  
□ Decreased water intake □ CHF □ Liver cirrhosis   
□ Renal failure □ 
 
Nephrotic 
syndrome 
□ SIADH    
 
□ 
 
Decreased salt intake □ Drugs □ Glucocorticoid deficiency   
□ Hypothyroidism  □ 
 
Psychogenic 
polydepsia 
□ Hyperglycemia 
□ Others     
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Risk factors: 
□ Art. Hypertension □ Diabetes mellitus □ Pneumonia 
□ Congestive heart 
failure 
□ Renal failure □ Others 
 
 
Clinical picture and complications: 
□ Nausea □ Vomiting □ Loss of appetite 
□ Lethargy and fatigue □ Muscle weakness □ Headache 
□ Low concentration  □ Cofusion □ Irretability 
□ Drowsiness □ Coma □ Seizures 
□ Syncope □ Falls or trauma □ Ataxia 
□ Cardiac arrest □ Respiratory arrest □ Other symptoms 
 
 
Investigations on admission: 
 
Blood pressure (mmHg) ………… LDL (mmol/l) ………… 
Coin test (sec) ………… HDL (mmol/l) ………… 
BIA (L) ………… Serum sodium (mmol/l) …………  
Hemoglobin (mmol/l)………… Serum potassium (mmol/l) ………… 
Hematocrit (%)………… Serum osmolality (mOsm/kg) …………  
WBC (Tsd./µl) …………          Urinary sodium (mmol/l) …………  
CRP (mg/l) ………… Urinary potassium (mmol/l) ………… 
Glucose (mmol/l) ………… Urinary osmolality (mOsm/kg) …………  
Urea (mmol/l) ………… S.Cortisol (nmol/l) …………  
Uric acid (µmol/l) ………… TSH (mU/l) ………… 
Serum creatinine (µmol/l) …………  FT4 (pmol/l) ………… 
Serum albumin (g/l) ………… Aldosterone (pmol/l) …………  
Triglyceride (mmol/l) …………  Renin (pmol/l/hr) …………  
Total cholestrol(mmol/l) …………  NT-proBNP (pg/ml) ………… 
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Investigations at discharge: 
 
Blood pressure (mmHg) ………… NT-proBNP (pg/ml) …………  
Coin test (sec) ………… Serum sodium (mmol/l) …………  
Urea (mmol/l) …………  Serum potassium (mmol/l) …………  
Uric acid (µmol/l) …………  Serum osmolality (mOsm/kg) …………  
Serum creatinine (µmol/l) ………… Urinary sodium (mmol/l) …………  
Aldosteron (pmol/l) ………… Urinary potassium (mmol/l) …………  
Renin (pmol/l/hr) …………  Urinary osmolality (mOsm/kg) ………… 
 
 
Drugs implicated  in development of hyponatremia 
 
□ Amiloride or triamterene 
□ Spironolactone 
□ Loop diuretics 
□ Thiazides 
□ ACE inhibitors or ARBs 
□ Beta blockers 
□ Moxonidine or clonidine 
□ NSAID 
□ Benzodiazpines 
□ Antidepressants: SSRI or tricyclic anti-depressants 
□ Antipsychotics: Phenothiazines or haloperidol 
□ Antiepileptic drugs: Carbamazepine or valproate 
□ Anticancer drugs 
□ Pain killers: Acetaminophen or opiates 
□ Antidiuretic hormone analogues: Oxytocin 
□ Hypoglycemic agents: Metformin or tolbutamide or chlorpropamide 
□ Antibiotics: Ciprofloxacin, co-trimoxazole 
□ Antiarrhythmic drugs: Amiodarone or  propafenone 
□ Theophylline 
□ Proton pump inhibitors 
□ Bromocriptin 
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□ Clofibrate 
□ Others 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79 
 
 
 
  
   Zentrum für Innere Medizin 
Medizinische Klinik II 
Abteilung Gastroenterologie und 
Endokrinologie/Stoffwechsel 
Sektion  
Endokrinologie/Stoffwechsel 
Leiter: Prof.Dr. H.S. Willenberg 
Ernst-Heydemann-Str. 6 
18057 Rostock 
Tel.: +49(0) 381 4947521 
Fax: +49(0) 381 4947522 
e-mail: 
Holger.Willenberg@ uni-rostock.de 
Station 12:Tel.: 0381/494-7525 / 7527 
Ambulanz: Tel.: 0381/494-7599 
Notfälle bitte über Station 12 
 
 
 
  
 
   
   
Betr.: Rostocker Hyponatriämiestudie im Rahmen des Konzeptes: 
»Wo Zucker ist, ist auch Salz« 
 
Eine Studie zur Ermittlung Ursachen von Störungen und Parametern des 
Volumenstatus bei Patienten mit Hyponatriämie. 
Sehr geehrte Patientin, sehr geehrter Patient, 
 
in unserer Sektion für Endokrinologie und Stoffwechselerkrankungen untersuchen wir 
bei unseren Patienten den Zucker- und Salzstoffwechsel. Hier scheint es enge 
Verbindungen zwischen beiden Stoffwechselwegen zu geben. Bisher sind diese 
Wechselwirkungen aber nicht gut genug erforscht und beschrieben. Deshalb führen 
wir zu diesem Thema eine Studie durch. In dieser Studie werden wissenschaftlich die 
Ursachen, Symptome, hormonellen Veränderungen und die Wirksamkeit der 
Behandlung von Patienten mit Hyponatriämie untersucht. Unter einer 
»Hyponatriämie« versteht man einen zu niedrigen Natriumspiegel im Blut bzw. einen 
»Salzmangel«. 
Wenn Sie eine Hyponatriämie haben, werben wir um Ihre Teilnahme an dieser 
Studie. 
Wir würden uns freuen, wenn wir Ihre Aufmerksamkeit geweckt haben. 
Mit besten Grüßen, 
Ihre 
 
Fr. cand. med. Hadeel Ghaleb   Prof. Dr. med. Holger S. Willenberg 
Studienärztin     Sektionsleiter 
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Sehr geehrte Patientin, sehr geehrter Patient, 
 
Ihre Ärztin/Ihr Arzt hat Ihnen angeboten, an dieser Studie teilzunehmen. Bevor Sie 
eine Entscheidung treffen, lesen Sie bitte dieses Informationsblatt sorgfältig durch. 
Bitte stellen Sie alle Fragen zur Registerstudie, die für Sie wichtig sind. Diese 
Einverständniserklärung beinhaltet möglicherweise Begriffe, die Sie nicht kennen. 
Bitte fragen Sie Ihre Ärztin/Ihren Arzt oder das Studienpersonal, wenn Sie Wörter 
oder Begriffe nicht verstehen. Durch die Unterzeichnung dieser 
Einverständniserklärung stimmen Sie zu, den Prüfärzten (die Ärztinnen und Ärzte, 
die sich um die Registerstudie kümmern) Ihre medizinischen Informationen zur 
Verfügung zu stellen. Sie können Ihr Einverständis jederzeit auch ohne Angabe von 
Gründen zurückziehen/widerrufen. Dadurch entstehen Ihnen keine Nachteile. 
 
Leitender Prüfarzt: Prof. Dr. med. Holger S. Willenberg 
 
Studienärztin: Frau cand. med. Hadeel Ghaleb 
 
24-Stunden-Telefonnummer: 0381 / 494-7525 
 
 
1.  HINTERGRUND UND ZWECK DER REGISTERSTUDIE 
Die »Hyponatriämie« ist eine sogn. »Elektrolytstörung« bzw. »Blutsalzstörung«, bei 
der die Salzmenge (Natriumkonzentration) im Blut niedriger als normal ist. Die 
Hyponatriämie ist die häufigste Elektrolytstörung und tritt oft bei Krankenhaus-
Patienten auf. Sie wird mit vielen Krankheiten und Medikamenten in Zusammenhang 
gebracht, unter anderem Erkrankungen der hormonellen Regulation (z.B. SIADH-
Syndrom, Nebennierenunterfunktion, Schilddrüsenunterfunktion), der Lungen, 
Nieren, Herzschwäche, Leberzirrhose und bösartigen Erkrankungen. Es stehen 
verschiedene Möglichkeiten zur Behandlung der Hyponatriämie zur Verfügung. 
Der Zweck dieser Untersuchung ist es, die verschiedenen Ursachen und 
Behandlungen (auch ohne medikamentöse Behandlung) der Hyponatriämie zu 
vergleichen. Ihnen wurde angeboten, an dieser Studie teilzunehmen, weil Ihre 
medizinischen Informationen dabei helfen können, mehr über die Hyponatriämie und 
ihre Behandlung im Krankenhaus zu erfahren. 
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2. BESCHREIBUNG DER REGISTERSTUDIE 
Diese Studie sammelt Informationen über Patienten, deren Natriummangel als Folge 
verschiedener Erkrankungen im Krankenhaus behandelt wird, und vergleicht die 
Wirksamkeit verschiedener Therapiemöglichkeiten in Bezug auf die Ursachen. Die 
Registerstudie erfasst außerdem Informationen über den Krankenhausaufenthalt 
(z.B. seine Dauer) und darüber, wie die Hyponatriämie während des 
Krankenhausaufenthalts diagnostiziert und behandelt wird. Ziel ist es, ungefähr 100 
Patienten mit Hyponatriämie in diese Registerstudie aufzunehmen. 
 
3. TEILNAHME AN DIE STUDIE 
Ihre Prüfärztin/Ihr Prüfarzt hat geprüft, ob Sie für die Teilnahme an dieser 
Registerstudie in Frage kommen. Sollten Sie sich für eine Teilnahme entscheiden, 
werden Sie gebeten, diese Einverständniserklärung sorgfältig zu lesen und nach 
Klärung aller Ihrer Fragen zu unterzeichnen. Mit Ihrer Unterschrift geben Sie Ihre 
Einwilligung zur Teilnahme an dieser Registerstudie. Ist diese Einwilligung erfolgt, 
wird Ihr Prüfarzt Daten aus Ihrer Patientenakte erfassen, einschließlich 
»demographische« Daten (z.B. Alter, Geschlecht, Gewicht, u.ä.), die Vorgeschichte 
Ihrer Krankheit, Ihre aktuellen Beschwerden, Ihre Flüssigkeitsaufnahme und –
ausscheidung, Ihre Laborergebnisse, die Befunde der durchgeführten 
Untersuchungen, Symptome in Verbindung mit der Hyponatriämie, Medikamente, 
die Sie einnehmen und Informationen zu Ihrer Entlassung. Sie werden 
ausschließlich durch Ihre Ärztinnen und Ärzte des medizinischen Zentrums 
behandelt, es finden keine zusätzlichen Untersuchungen oder Behandlungen statt 
und Sie müssen keine weiteren Angaben machen. Informationen werden bis zu Ihrer 
Entlassung aus dem Krankenhaus erfasst. 
 
4. BEHANDLUNGSMÖGLICHKEITEN 
Über die für Sie am besten geeignete Hyponatriämie-Behandlung entscheidet Ihre 
Ärztin/Ihr Arzt und nicht die Registerstudie. Sie können sich auch entscheiden, nicht 
an der Registerstudie teilzunehmen. Wenn Sie sich gegen eine Teilnahme 
entscheiden, erhalten Sie die gleiche medizinische Versorgung, Ihre Daten werden 
jedoch nicht erfasst. 
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5. DAS RECHT, FRAGEN ZU STELLEN UND/ODER DIE REGISTERSTUDIE ZU 
BEENDEN 
Durch die Unterzeichnung dieser Einverständniserklärung verzichten Sie nicht auf 
Ihre gesetzlichen Rechte. Ihre Teilnahme an dieser Registerstudie ist absolut 
freiwillig. Sie haben das Recht, die Registerstudie jederzeit zu beenden. Sie müssen 
weder Nachteile/Sanktionen befürchten noch auf irgendwelche Vorteile verzichten. 
Wenn Sie sich entscheiden, nicht teilzunehmen oder Ihre Teilnahme an dieser 
Registerstudie abzubrechen, werden sich die Prüfärztin/der Prüfarzt und ihre/seine 
Kollegen weiterhin um Ihre medizinische Versorgung kümmern.  
Sie haben das Recht, jederzeit Fragen zur Registerstudie zu stellen. Während Ihrer 
Teilnahme an dieser Registerstudie beantworten Ihre Prüfärztin/Ihr Prüfarzt oder 
ihre/seine Kollegen alle Ihre Fragen zur Registerstudie. Bei Fragen zu Ihren Rechten 
als Registerstudienpatient wenden Sie sich bitte an Ihre Studien- und Prüfärzte bzw. 
die Stations- und Oberärzte. Alle Informationen, die während dieser Registerstudie 
verfügbar werden und die Ihre Ärztin/Ihr Arzt als wichtig in Bezug auf Ihre 
Bereitschaft für eine weitere Teilnahme erachtet, werden Ihnen mitgeteilt. 
Sie haben außerdem das Recht, Ihre persönlichen Daten, die während der 
Registerstudie erfasst werden, einzusehen. Sie können jederzeit Ihr Recht auf 
Einsichtnahme und Berichtigung ausüben. Zur Ausübung Ihres Rechts (auf 
Einsichtnahme und Berichtigung Ihrer medizinischen Daten oder andere Anfragen) 
wenden Sie sich an die Ärztin/den Arzt, die/der Sie während der Registerstudie 
betreut. 
 
6.  NUTZEN 
Die Registerstudie gibt weder eine bestimmte Behandlung noch ein bestimmtes 
Medikament für die Behandlung Ihrer Hyponatriämie vor. Daher gewinnen Sie 
keinen gesonderten Nutzen durch ein bestimmtes Medikament. Jedoch kann Ihre 
Teilnahme an dieser Registerstudie dabei helfen, mehr über die Hyponatriämie zu 
erfahren und so anderen Patienten zukünftig nutzen, auch wenn Sie persönlich 
keine Vorteile davon haben. Des Weiteren entstehen Ihnen keine Kosten für die 
Teilnahme an dieser Registerstudie. 
 
7. RISIKEN UND UNANNEHMLICHKEITEN 
Diese Registerstudie erfasst Informationen darüber, wie die Hyponatriämie 
standardmäßig an den jeweiligen teilnehmenden medizinischen Zentren behandelt 
wird. Patienten erhalten keine Prüfpräparate (d.h. keine Medikamente, die sich noch 
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in Erprobung befinden) oder zusätzliche Untersuchungen im Rahmen dieser 
Registerstudie; daher sind keine körperlichen Risiken oder zusätzliche Belastungen 
mit der Teilnahme an der Registerstudie verbunden. 
 
8.  KÖRPERLICHE SCHÄDEN 
Sie nehmen freiwillig an dieser Registerstudie teil. Sie erhalten während der 
Registerstudie keine Prüfmedikamente und es werden keine zusätzlichen 
Untersuchungen durchgeführt. Die Registerstudie sammelt Informationen über die 
Behandlung, die Sie für Ihre Hyponatriämie erhalten. Mit Ihrer Teilnahme an dieser 
Registerstudie ist deshalb kein Risiko eines körperlichen Schadens zu erwarten. 
 
9. VERWENDUNG DER REGISTERSTUDIENERGEBNISSE UND 
VERTRAULICHKEIT 
Das Forschungspersonal sowie Aufsichtsbehörden erhalten direkten Zugriff auf Ihre 
Originalpatientenakte zur Überprüfung der Daten. Diese Personen müssen ggf. auch 
Informationen aus Ihrer Patientenakte kopieren. Alle Informationen, die Sie 
identifizieren könnten, werden gelöscht. Der Schutz Ihrer persönlichen Daten wird im 
Rahmen der anwendbaren Gesetze und Bestimmungen gewahrt. Durch die 
Unterzeichnung dieser Einverständniserklärung erlauben Sie dem Sektionspersonal, 
diese Registerstudie durchführen und den Aufsichtsbehörden den Zugriff auf Ihre 
Daten. 
Die Erfassung und Übermittlung der medizinischen Daten aus dieser Registerstudie 
an Aufsichtsbehörden erfolgt unter Einhaltung der Datenschutzrichtlinien. Wenn 
Ergebnisse dieser Registerstudie in medizinischen Fachzeitschriften veröffentlicht 
werden, wird Ihre Identität nicht offengelegt. 
Ihr medizinisches Zentrum folgt etablierten Verfahren zur Wahrung des 
Datenschutzes. Ihre Daten erhalten lediglich einen Nummerncode. Niemand wird Sie 
anhand dieses Nummerncodes identifizieren können. Es werden keine 
Informationen, die Ihre Identität offenlegen könnten, veröffentlicht oder bei 
wissenschaftlichen Konferenzen vorgestellt. 
Wenn Sie Bedenken hinsichtlich Vertraulichkeit, Übermittlung oder Sicherheit der 
von Ihnen oder über Sie bereitgestellten Daten haben, besprechen Sie dies bitte mit 
Ihrer Ärztin/Ihrem Arzt, die/der Sie während der Registerstudie betreut.  
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10. BEENDIGUNG DER TEILNAHME 
Unter bestimmten Umständen kann Ihre Teilnahme an dieser Registerstudie ohne 
Ihre Zustimmung beendet werden, z.B. wenn nicht alle Einschlusskriterien 
(Anforderungen) für diese Registerstudie erfüllt sind. Außerdem kann die 
Universitätsmedizin entscheiden, die Registerstudie jederzeit zu beenden. Wenn 
Ihre Teilnahme an dieser Registerstudie beendet wird, erfahren Sie die Gründe 
hierfür. Die medizinische Versorgung Ihrer Hyponatriämie wird selbstverständlich 
ohne Unterbrechung weitergeführt. 
 
11. PATIENTENEINWILLIGUNG 
Die Registerstudie wurde mir ausreichend erläutert und ich hatte die Gelegenheit, 
Fragen zu stellen. Alle Fragen, die ich zu diesem Zeitpunkt hatte, wurden zu meiner 
Zufriedenheit beantwortet. Ich verstehe, dass ich ohne meine Einwilligung nicht an 
dieser Registerstudie teilnehmen kann. Ich habe das Recht, weiterhin Fragen zu 
stellen und Antworten zu erhalten. Ich kann jederzeit meine Teilnahme beenden. 
Dies wird meine weitere medizinische Versorgung an der Universiätsmedizin 
Rostock in keinster Weise beeinträchtigen. 
Ich habe diese Einverständniserklärung und die Beschreibung der Registerstudie 
gelesen und verstanden. Ich unterzeichne freiwillig diese Erklärung als Nachweis 
meiner Entscheidung, an dieser Registerstudie teilzunehmen. Ich werde eine Kopie 
dieser unterzeichneten Einverständniserklärung erhalten. 
 
     
Name, Vorname 
(Patient) 
 Ort, Datum  Unterschrift 
     
Name, Vorname 
(Arzt) 
 Ort, Datum  Unterschrift 
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